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ABSTRACT: To study the prevalence of IgG subclasses (IgG1 and IgG3) in antenatal 
alloimmunized women in South India 
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Objective: To study the prevalence of IgG subclasses (IgG1 and IgG3) in antenatal 
alloimmunized women in South India and to correlate it with occurrence and severity of 
Hemolytic Disease of Fetus and Newborns (HDFN). 
Methodology: 85 antenatal women with a positive antibody screen were included in this 
study, irrespective of parity and period of gestation. The antibodies were identified and IgG 
subclass (IgG1/ IgG3) was determined using the “DAT IgG1/IgG3 ID card from DiaMed 
Gmbh, BIO-RAD which utilizes the column agglutination technique. These pregnancies were 
followed up to see the outcome. The newborn was identified to “have or not have HDFN” 
using the DAT test and further categorized into Mild/ Moderate/Severe HDFN based on the 
modality of treatment required. The prevalence of IgG1/IgG3 subclasses was calculated in 
the alloimmunized antenatal. The categorical data including disease IgG subclass, severity of 
HDFN and correlation with DAT strength was calculated using Pearson’s chi square test. The 
severity of HDFN was correlated with the IgG (IgG1 and IgG3) subclasses and antibody titre 
levels in maternal serum using the univariate and binary logistic regression analysis.     
Results and Conclusion: The prevalence of IgG subclasses in our study was found to be, 
20% for IgG1, 4% for IgG3, 25% for IgG1+ IgG3, 51% had neither IgG1 and/or IgG3. 
Among the 57 newborns at risk of HDFN, we found a highly significant difference between 
disease severity and absence / presence of IgG1/IgG3 – either singly or in combination 
(p<0.001). Assessing disease severity in  low and intermediate antibody titre level groups 
showed a significant difference with more severe disease in those with IgG1 and / or IgG3 as 
compared to those who were negative for both these subclasses (p<0.001). The binary logistic 
regression analysis showed the odds of severe HDFN to increase an additional  seven times 
stepwise , the lowest being  in patients with neither IgG1/IgG3, to having either one of them, 
to having both these subclasses together (p<0.05, CI between 1.5-31.89). DAT was positive 
in 37 of 57 babies. Severity of HDFN was significantly associated with increasing DAT 
strength (p<0.001)  
We conclude that the presence of IgG1/IgG3 subclass impacts significantly on the severity of 
HDFN. This effect continues to be significant even when titres are low. These mothers 
therefore require closer antenatal monitoring, and babies in this group require closer follow 
up to allow for appropriate and timely intervention. A stronger DAT reflects as HDFN with 
greater severity. This study identified the significance of IgG subclass as an independent 
prognostic marker for HDFN which can easily be incorporated into routine clinical practice.   
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AIM: 
 
 
To study the prevalence of Ig G subclasses (IgG1 and IgG3) in antenatal alloimmunized 
women in South India 
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OBJECTIVES: 
 
 
1. To study the prevalence of Ig G subclasses (IgG1 and IgG3) in antenatal 
alloimmunized women in South India 
 
2. To correlate the IgG subclass with occurrence and severity of Hemolytic Disease of 
Fetus and Newborn (HDFN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
INTRODUCTION: 
 
Haemolytic disease of newborn is a condition characterized by rapid destruction of an 
infant’s red cells by antibodies transferred from the mother through the placenta, which 
develop as a result of sensitization to the paternal antigens. The symptoms may vary, ranging 
from mild anaemia and jaundice to a severe condition leading to cardiac failure, hydrops 
fetalis or still birth. It has been a major challenge for obstetricians and neonatologists for the 
longest time and since the process of destruction begins as early as during the intrauterine 
phase of pregnancy it has more accurately been termed as haemolytic disease of foetus and 
newborn (HDFN) .  
In present day clinical practice even with the best of diagnostic and therapeutic measures 
available, HDFN should be considered as a possibility in the following situations,(1) 
 A positive maternal antenatal antibody screening and/or diagnosed severely 
anemic/hydropic fetus; 
 A positive DAT carried out on the fetus or newborn’s sample 
 Rapidly developing indirect hyperbilirubinaemia in a newborn, not explained by 
maternal antenatal antibody screening (as in the case of very rare antibody 
specificities) 
 Haemolysis in the newborn detected on blood film examination, characterized by 
reticulocytosis or presence of increased nucleated red cells. 
 
The outlook towards HDFN has shifted drastically over the last few decades. While earlier 
the focus was more towards cure and appropriate management of a newborn afflicted by the 
disease, presently many new methods are being implemented and studied for prevention of 
the same. Serological tests, radiological interventions and immunoglobulin prophylaxis are 
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all works in various fields which have contributed in decreasing the burden of HDFN 
globally. There have also been remarkable advances in the treatment modalities involved 
both prenatal and post-natal, in the form of Doppler monitoring and IV Immunoglobulin 
treatment.   
HDFN is mainly identified by anaemia and indirect hyperbilirubinemia in a newborn with a 
Direct Antiglobulin Test (DAT) positive. DAT helps detect maternal antibodies that coat the 
foetal red cells; the presence of the corresponding alloantibody in the mother is identified by 
an Indirect Antiglobulin Test (IAT). As per BSCH guidelines 2008, “All infants born to 
women who have clinically significant antibodies should be closely observed for evidence of 
HDN. A DAT should be performed and if positive, hemoglobin and bilirubin levels should be 
measured”.(2) 
Antibody screening test is now routinely done for all antenatal women during the course of 
their pregnancy in our institution. However, a positive antibody screen does not necessarily 
correlate all the time with the occurrence or severity of HDFN. Numerous studies in literature 
have showed that the IgG subclass – particularly the presence of IgG1 and IgG3 either singly 
or in combination, impacts on the presence and severity of HDFN(3,4). However, there is 
very limited literature from India.  
The primary objective of undertaking this study was to look at prevalence of IgG1 and IgG3  
subclasses in all sensitized women and to observe if the presence of these IgG subclasses 
contributed to the severity of disease. This would have a great clinical impact if a correlate 
were to be found. If this test was found useful in predicting severity of HDFN, it would 
greatly impact clinical practice by allowing the clinician greater antenatal and neonatal 
monitoring / intervention. 
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Identifying IgG subclasses, as a predictor for severity of HDFN as both qualitative and 
quantitative assays have been described with most studies having been carried out in the 
West. Platforms that have been used include Enzyme linked immune sorbent assay (ELISA) 
and flow-cytometry. However these are not very viable options for routine use considering 
cost, ease of operation and the necessity to batch on the former. The Column agglutination 
technology (CAT) is an easily available and commonly used platform in the immuno-
haematology arena. Reliable, robust and used for many tests including blood grouping, 
compatibility testing and antibody screening, when the IgG sub classing was introduced on 
this platform, it was found to gain wide acceptance. A study comparing the efficacy of 
detection of DAT positivity on CAT vs. flow flow-cytometry was done by Dittamar et al. in 
the year 2001, and they suggested that CAT was as sensitive a platform to detect red cell 
bound antibodies as the flow-cytometry. The CAT offers greater sensitivity than other 
platforms used in immunohaematology as demonstrated by Sudipta et al who have described 
their experience comparing CAT and tube technique for patients of AIHA. In addition to 
greater sensitivity, they also reported that the strength of reactions were stronger on this 
platform..(5)  Not only is the CAT a more viable option for a developing country like India 
because of the cost benefit, they have also shown comparable results with flow cytometry. 
While the latter is mostly used as a research tool, it also requires expertise in carrying out the 
test. Keeping in mind the cost- benefit aspect of a new test and its role in serving our 
population, the column agglutination technology which is an easily available and a reliable 
platform used in many blood banks was considered an appropriate platform for the same.   
The major advantages of using the CAT lies in its simple procedure, reproducibility of 
results, ease of standardization and familiarity of use in a blood bank set up. Moreover the 
test in comparison to other conventional methods requires less volume of sample.(6) 
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The catalytic factor for this study was the limited literature available about the prevalence of 
IgG subclasses in the Indian subcontinent. Considering the clinical impact this could have in 
terms of minimising morbidity and mortality secondary to HDFN, we aimed at studying the 
prevalence of IgG1 and IgG3 on the CAT platform and to correlate it with the severity of 
HDFN in our tertiary hospital in South India. 
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REVIEW OF LITERATURE: 
 
The pathophysiological basis of HDFN began to be studied at the beginning of the last 
century to increase knowledge about the condition and achieve methods to prevent it. It has 
been an important cause of foetal loss and neonatal mortality, but the declining incidence in 
recent times is primarily attributed to the cooperation between pathologists, paediatricians, 
haematologists, obstetricians, immunologists, geneticists and transfusion medicine 
specialists. Despite all the advances in this field it remains a serious condition and is not 
managed successfully in all cases despite successful immunological prophylaxis or close 
monitoring. 
HISTORY:  
HDFN an important cause of foetal loss and death of newborn babies and is said to have been 
first described by a French midwife named Louise Bourgeois in 1906, who worked at the 
royal court of King Henry IV. While assisting in the delivery of twins she noted that—one 
baby was swollen and died soon after birth, while the other baby developed jaundice and died 
several days later.(7)(8) For the next 300 years, many similar cases were described in which 
newborns failed to survive due to unexplainable cause.  
     Hippocrates, mentioned a condition known as fetus carnosus, which is thought by medical 
historians to represent present day foetal hydrops.(9) The first descriptive work which 
reviewed the condition from the point of view of morphology and pathogenesis of the 
condition was that of Schridde in 1910. He suggested, that the anaemia was  characteristic by 
extramedullary haematopoiesis in the spleen and liver and increased number of immature 
erythrocytes in the peripheral blood due to destruction of red cells(9) . The actual name for 
the phenomenon – “erythroblastosis”, was coined by Rautmann. Later in 1932 Diamond et al. 
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coined the term “erythroblastosis fetalis” and for the first time identified it as a syndrome 
linking three important features, that is, congenital anaemia, jaundice, and hydrops fetalis 
with evidence of extramedullary haematopoiesis and erythroblastemia(10).The fact that the 
anatomical and pathological part of HDFN could be contributed by an “antigen-antibody 
reaction” was a major path breaking  work described by Ruth Darrow, and was accepted in 
the medical community only following much work and contemplation. (11) In 1900, 
Landsteiner and colleagues discovered the ABO blood group system, for which he also 
received the Noble prize and later in the 1930s and 1940s, Landsteiner and Weiner described 
the Rhesus (Rh) blood groups. Levine and associates described the link between the Rh 
groups and HDFN.  Following which, Auden described a series of fatal cases of severe 
neonatal jaundice in families which formed a  major contribution in understanding  Rh 
antibody associated HDFN.(12)The work and studies of these scientists has been the stepping 
stone which has lead to the present day knowledge of HDFN. 
EPIDEMIOLOGY:  
Following the implementation of Rhesus D immunoprophylaxis, HDFN due to ABO 
incompatibility and other alloantibodies has emerged as a cause for concern other than the 
widely known Rh alloantibody (irregular/ unexpected antibody). ABO incompatibility 
between the mother and the baby occurs in about 15-20% of all pregnancies, which produces 
HDFN in 10% of these cases.
 
Though ABO blood groups have predominantly IgM 
antibodies, 40-93% of the group O mothers also have IgG anti-A and anti-B antibodies which 
is able to cross the placenta and cause fetal cell destruction.(13)(14) In developing countries, 
anti-D still remains a common alloantibody encountered in pregnant women, and many Asian 
countries have identified alloantibodies other than anti-D as a cause of moderate-severe 
hemolytic disease.(15)  
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WORLD SCENARIO: Alloimmunization has been extensively studied in different countries 
and regions, with frequency in pregnant women being found to range from 0.4% to 2.7% 
worldwide.(16)(17) Published data suggests that the rate of alloimmunization may be greatly 
dependent on the geographical boundaries, and to this effect Lee et al, suggested that 
antenatal antibody screening for Chinese women may not be worthwhile due to prevalence of 
alloimmunization being as low as 0.79%, unless women were D antigen negative or had a 
significant history of HDFN. (18)  
 
Table 1: Previous studies on alloimmunization in pregnant women 
 
Authors Place Year Overall Prevalence 
 
Varghese et al Vellore, India 2013 1.48% 
Pahuja S et al. Delhi, India 2008-09 1.25% 
Koelewijin JM et al. Netherlands 2008 1.232% 
Al-Ibrahim et al. Saudi Arabia 2008 1.92% 
Gottvall et al. Sweden 2008 0.4% 
Lurie et al. Israel 2003 RHD positive 0.2%, 
RHD negative 
women 0.9% 
Lee et al. China 2003 0.79% 
Chandrasekar et al. Ireland 2001 0.53% 
De Vrijer et al Netherlands 1999 2.71% 
Howard et al UK 1998 1% 
Filbey et al. Sweden 1995 0.57% 
Courtesy: Pahuja S et al.(19) 
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INDIAN SCENARIO: There is limited data on the prevalence of alloimmunization in India. 
However one study conducted in Delhi, North India, found alloimmunisation in 1.2% with 
Anti-D antibodies contributing to 78% cases. This was  followed by anti-C (11.76%),  and 
Anti-M with a frequency of 3.92%.(19)   
CMC, TAMIL NADU: According to a study done earlier in our tertiary hospital which looked at 
the profile in the South Indian population, the prevalence of alloimmunization was found to 
be 1.48% in pregnant women.  In 37% of these women the allo-antibodies could not be 
identified; however in the remaining 63% of women, 54 antibodies were characterized. A 
total of 40 clinically significant antibody specificities were identified among 36 women, of 
whom four were Rh(D) positive. Allosensitization with clinically significant antibodies was 
found in 9.43 per cent Rh(D) negative and in 0.08 per cent Rh(D) positive women. Anti D 
was the most frequent antibody found in 8.85 per cent Rh(D) negative women. The remaining 
clinically significant antibodies identified included anti-C, c, E, Jk
a
, Jk
b
, M and S. In Rh(D) 
negative women, anti-D and antibodies of the Rh system contributed 83.3 and 94.4 per cent 
of clinically significant antibodies.(20) 
DISEASE BURDEN IN INDIA:  Rh alloimmunozation affects a large number of pregnancies 
every year, having both health and financial implications. It has been seen that without proper 
management and treatment 50% affected fetus of HDFN would succumb to death, and with 
timely measures and transfusion support, there is hope for 90% survival rate in affected 
pregnancies. In developing countries like India, without a proper antenatal prophylaxis 
programme in place, HDFN could lead to loss or damage of approximately 50,000 foetus per 
year.(21) This data highlights the need for evidence based universal guidelines for antibody 
screening in pregnant women, in developing countries such as India for proper management 
of child birth.  
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PATHOGENESIS OF HDFN:  
The pathogenesis of HDFN includes the sensitization of a mother to a paternal antigen she is 
negative for, through the fetus which is positive for the same. This may occur with the 
slightest of fetomaternal haemorrhage, more commonly occurring during delivery or 
sometimes even during the third trimester. The event sensitizes the mother for life and she 
develops IgG antibodies. In subsequent pregnancies the mother develops these IgG antibodies 
in higher titres due to an amnaestic response, which cross the placenta and bind to the fetal 
red cells. These sensitized fetal red cells attach to the receptors of macrophages in the 
reticulendothelial system, particularly the bone marrow and are rapidly destroyed and 
removed from the circulation. This rapid destruction leads to haemolysis in the new born. 
The pathogenesis of the disease may be broadly divided into three parts: 
1. Alloimmunization of the mother  
2. Transfer of these irregular antibodies to the fetus through the placenta  
3. Destruction of fetal red cells. 
BIOCHEMISTRY OF IgG ANTIBODIES:(22) 
Immunoglobulin molecules are proteins made up of four polypeptide chains- two light chains 
with molecular weight of approximately 22,500 Daltons and two heavy chains of molecular 
weight 50,000-75,000 Daltons which are interconnected by covalent disulfide bonds. The 
heavy chains are also held together by disulfide bonds at their hinge region. There are a total 
five types of heavy chains (gamma, alpha, meu, delta, and epsilon) and two types of light 
chains, named kappa (κ) and lambda (λ) respectively. The light chains are the same in the 
five types of immunoglobulin molecules it is the heavy chain that varies for each type.  
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Immunoglobulin are protein molecules with an amino (-NH2) and a carboxyl (-COOH) end. 
When treated with papain enzyme an immunoglobulin is divided at certain specific points to 
form fragmented units which include: one crystalline Fc fragment and two antigen binding- 
Fab segments. The Fc region extends from the carboxyl terminal to the hinge region and is 
primarily responsible for monocyte binding and complement fixation, and in IgG subtype of 
immunoglobulin it is the Fc fragment which crosses the placenta and is responsible for the 
pathophysiology of HDFN. The Fab fragments extend from the amino terminal to the hinge 
region of the molecule. 
The domains of an immunoglobulin molecule are made up of regions of both heavy and light 
chains folded into globular structures or loops, and these are made up of approximately 110-
120 amino acids. The domains consist of variable (V) and constant (C) regions made up of 
heavy and light chains. The number of domains is dependent on the immunoglobulin isotype 
and IgG molecules have three constant heavy chain regions (CH1, CH2, CH3).The hinge 
region of the immunoglobulin structure exists between the CH1 and CH2 domains of the 
heavy chain. Minor differences in these hinge regions are used to categorize the four 
subclasses of IgG. In IgG molecules there is a specific constant heavy chain region (CH2 and 
CH3) which allow for attachment of Fc receptors of monocytes and macrophage cells.  
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Site for attachement to
phagocytic red cells
Disulfide bonds
Site for attachment to complement
Site for attachment 
to antigen
Variable region
Constant region
 
Fig 1: Depicting basic structure of an IgG molecule 
 
IgG antibodies can be subdivided into four subclasses (IgG1, IgG2, IgG3 and IgG4), on the 
basis of minor structural differences in the hinge region of the IgG structure and these can be 
separated out by electrophoresis. The overall ratio of κ to λ in human IgG is 2:1, but the ratios 
is 1:1 and 8:1 for individual IgG2 and IgG4 subclasses respectively. The disulfide bonds 
linking the heavy chains also acts as factor for structural variation among the different 
subclasses. While IgG1 and IgG4 have two bonds each, IgG2 and IgG3 have four and five 
bonds respectively. The disulfide bond lends flexibility to the hinge regions of the subclasses 
of IgG molecule and the distance the Fab fragment can cover determines the antigen it can 
accommodate.(23) 
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 Each of the subclasses exhibit differences in properties including placental transfer and 
complement fixation. While IgG1 and IgG3 bind to complement C1q molecule more strongly 
than IgG2. IgG4 doesn’t bind at all and cannot activate the complement cascade. (24) 
Among blood group antibodies it has been observed that one particular blood group system is 
not necessarily a particular subclass alone. The Rh blood group system associated HDFN has 
commonly been attributed to IgG1 and IgG3 subclass, while IgG1 and IgG3 alone have been 
found responsible in the Kell and Duffy blood group system respectively. 
    TRANSFER OF ANTIBODIES FROM MOTHER TO FETUS:  
 
Of the five major classes of antibodies (IgG, IgM, IgA, IgD and IgE), IgG alone is capable of 
crossing the placenta. The transplacental movement of antibodies is an active process proved 
by the fact that that the immunoglobulin concentration in the fetus correlates positively with 
the gestational age, and the cord blood immunoglobulin level at term may exceed the 
respective maternal concentration. The movement of IgG is dependent on the interaction 
between the antibody molecule and the synctiotrophoblast Fc receptors and the process is 
most active in the third trimester.(25)(26). The structure of Fc receptors has been found to be 
unique and unlike those of other Fc receptors, and it is a distant member of MHC class I 
protein, dependent on β2 microglobulin for its functioning. Placental transfer of 
immunoglobulin G (IgG) has been demonstrated and studied by several investigators. It has 
been suggested that the α2 and β2 microglobulin domains of the Fc receptors interact with 
Cγ2 and Cγ3 domains of IgG molecule. (25) . 
   The physiologic process of IgG transfer to the fetus is responsible for providing the 
advantage of passive defence immunity to the newborn, but there are disadvantages in certain 
pathologic conditions. According to literature the Fc receptors transport IgG in a two-step 
process. IgG as a first step is engulfed non-specifically into acidic endosomes, which form 
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high affinity bonding between the respective receptors and IgG molecule at a pH of <6.5, 
following which, IgG-FcRn complexes are shuttled in transport vesicles to the basolateral 
surface where IgG is released at neutral pH of approximately 7.4. According to Martin et al. 
(2001) the pH-dependent interaction involves histidine residues on the Fc portion of IgG and 
residues on FcRn that are charged at acidic but not basic pH.(25) 
    IgG concentrations in the fetus rise slowly during the first half of gestation to reach levels 
between 10 and 20% of those found in the mother by 22 weeks gestation.(27)  In the first 
twelve weeks of gestation the transfer of antibodies may be slow and quite minimal. However 
if the mother has relatively potent amount of anti-D in high titres, the DAT for the fetal cells 
may show positive results as early as 6 to 10 weeks into the pregnancy. From twenty fourth 
week of pregnancy the transfer of antibodies has been shown to rise exponentially.(28) 
   Lastly, Hughes-Jones et al. calculated that the placental transfer of anti-D may be the rate-
limiting step in the reaction between anti-D in the maternal circulation and fetal red cells, and 
therefore diminished IgG transport on the corollary may result in unexpectedly mild 
HDFN.(29) 
FETAL RED CELL DESTRUCTION:  
Once the maternal irregular antibodies enter into the fetal circulation, they are free to bind to 
the corresponding antigens on the fetal red cells. However some of these antigens are not 
specific for erythroids for example the AB, Duffy and Kidd antigens which are also 
expressed on other tissues, thus binding of antibodies to the non-erythroid antigenic sites 
leads to decrease in effective antibody load which can cause red cell destruction. The Rh, MN 
and Ss antigens are expressed solely on erythroid cells, while Kell antigen is expressed both 
on erythroid and myeloid cells. 
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The placental barrier and variable expression of different antigens on the fetal red cells 
contribute to the degree of hemolysis which finally occurs. The red cell destruction can occur 
primarily by two methods, activation of the complement system or antibody mediated 
cytotoxicity. Complement activation is rare with IgG molecules, because it requires coming 
together of two molecules to bind to the C1q complement initiating protein.  
The sensitized fetal red cells are primarily destroyed by binding to the Fc receptor of 
macrophages in the reticuloendothelial system of the newborn, primary site being the spleen. 
The destruction of red cells is primarily intracellular and thus characterized by anaemia and 
hyperbilirubinemia.(30) 
 
     QUANTITATIVE AND QULITATIVE ASPECT OF ALLOIMMUNE RESPONSE 
IN HDFN:(29) 
 
A. Antibody concentration/titer levels: In present day clinical practice a sensitized antenatal 
woman undergoes close monitoring with antibody titer levels. The antibody titration is 
expected to indicate the concentration of antibodies and the capability of the same to cause 
HDFN. However the accuracy of titration is debatable according to literature. Gupte et al. in 
their work did not find a good correlation between Rh titer levels and disease severity. In 
recent advances other factors have been found to play a role in rise of Anti-D antibodies. 
The HLA phenotype of the mother is one such factor under consideration. HildCn et al. in a 
very advanced research have reported the HLA-DQB1 allele *0201 is associated with 
higher concentration of antibodies in maternal serum.(31) The significance of these and 
value as a prognostic marker are the challenges for the future. 
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B.  Antibody Subclass: A great amount of emphasis is laid on the association between IgG 
subclass and the extent of haemolysis in utero in the last decade of scientific research. 
However studies have not brought up uniform results. The conflicting outcome seen 
through the various studies is still debatable and newer methods are being applied for not 
only qualitative but quantitative analysis of the IgG subtypes in alloimmunized women.  
C. Antibody glycosylation: The IgG molecule contains a carbohydrate moiety within the Cy2 
domains which plays a critical role in stabilizing the tertiary structure of the antibody. The 
biological activity of the carbohydrate molecule has gained importance lately following 
experiments which have shown that aglycosylated form of anti-D is less efficient in causing 
moncyte and K cell mediated hemolysis than glycosylated forms. Hence it may be expected 
that anti-D secreted under conditions which favor the incorporation of relatively high levels 
of galactose such as condition of pregnancy is relatively a high risk for hemolysis compared 
to serum from a male.  
D. Placental transfer of antibodies: IgG antibodies cross over from the mother to the fetus by 
attaching to the Fc receptors. The IgG concentrations in the fetus rise rather slowly during 
the initial stages of pregnancy with a more steep incline in the third trimester or 22 weeks 
onwards when the levels in the fetus maybe almost 10-20% of that in the maternal serum. 
The rise is exponential after 22-24
th
 week of pregnancy, till about term when the fetal levels 
of IgG may even surpass the maternal levels. The steep rise of IgG levels in the fetus is an 
indication of the on-going development of the immunoglobulin transport between mother 
and fetus. The efficiency with which maternal IgG alloantibodies are transported is also 
suggested to impact the severity of fetal hemolysis.  
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ALLOANTIBODIES CAUSING HDFN:  
             The most common IgG red cell antibodies are anti-A and anti-B, and ABO incompatibility 
leading to HDFN can occur when the mother is blood group O and it is seen in only 1% 
mothers with ante-partum high titres of IgG antibodies. ABO HDFN is less severe as 
compared to other antibodies such as Anti-D and all antenatal and postnatal tests are poor 
indicators of ABO incompatibility.(32) ABO incompatibility may often be DAT negative and 
the peripheral smear of these babies shows prominence of spherocytes in contrast to Rh 
incompatibility which is DAT positive and predominantly shows nucleated red cells as a 
peripheral smear finding.(32)  
 Presently more than fifty different red cell antibodies have been identified which can lead to 
HDFN and almost all IgG types can cause red cell lysis.(33) Many of the red blood cell 
alloantibodies of the Rh system have been associated with HDFN; however, the severity of 
the disease is usually the greatest with anti-D and anti-D continues to be the commonest 
cause especially in developing countries, despite wide prevalent use of prophylactic Anti-D 
immunoglobulin prophylaxis during antenatal and postnatal period. The other frequent 
alloantibodies, among: Rh antigens (anti-c, anti-C, anti-e, anti -E), Kell antigens, Duffy 
antigens, Kidd and MNS antigens. Anti-c and anti-E are the most commonly implicated non 
D (Rh) antibodies in the pathogenesis of HDFN. Anti E-induced HDFN may also cause 
severe disease and require prenatal management.(34) (35)(36) The failure of some antibodies 
of other blood group systems to cause HDFN may be attributed to lack of the corresponding 
antigens on fetal red cells.(28) or absorption of antibodies by fetal antigen in the placenta (eg. 
Cromer system antigens)(37) 
The Kell blood group system which is the second most common blood group system 
associated with HDFN, was discovered in 1946 and was named after Mrs. Kelleher, a patient 
in who had borne a newborn with HDFN and had anti-Kell antibody identified. A total of 25 
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Kell antigens have been discovered over time and these are expressed in different frequencies 
in various populations. However the original K antigen is still considered the most significant 
in respect to incidence of HDFN. There are case reports due to other rarer Kell antigens. In 
contrast to the conventional Rh and ABO sensitization, HDFN due to Kell sensitization is 
caused by anti-K suppressing the fetal production of red cells. Kell antigens are unique in that 
they are expressed on the surface of red cell precursors, and anti-K promotes the immune 
destruction of K positive erythroid early progenitor cells by macrophages in the fetal liver. 
Since the red cell precursors do not contain hemoglobin, less bilirubin is released during the 
hemolysis, and jaundice in the newborn period is a less prominent feature, however, the 
underlying anemia may be severe due to overall suppression of the erythropoietic system.(38) 
Alloanti-Kp
a 
and Kp
b
, are
 
examples of rare, but clinically significant antibody against high 
frequency red cell antigen Kp
a
 and Kp
b
 respectively from the Kell system. Anti-Kp
b
 is 
capable of causing severe late onset HDN. There is a case report by Elhence et al. from India 
in which the baby showed manifestations of disease after almost one month of age, 
suggesting that infants born to irregular antibody positive mothers may required a more 
intensive investigation and monitoring for a longer period of time to diagnose immune 
mediated HDFN even if the newborn is asymptomatic initially.(39) Kpa, another Kell blood 
group antigen, occurs in less than 2% of Caucasians.(40) There are case reports of HDFN due 
to maternal anti-Kpa alloimmunization. However the disease severity may range from mild 
form  requiring only close monitoring to severe transfusion dependent disease.(41)(42) When 
a clinical picture of HDFN is encountered with DAT positive results, but a negative maternal 
antibody screen, the presence of antibodies to an uncommon red cell antigen must be 
considered. 
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In the MNS blood group antibodies, anti-S is more common than anti-s, and both are capable 
of causing severe hemolysis. Less common causes of HDN include anti-M, anti-N, anti-U, 
anti-Mi
a
, anti-Mt
a
, and anti-En
a
. Anti-M antibody induced HDFN has been reported in 
literature. Though mostly they tend to be IgM type of antibodies, they can also be IgG and 
lead to severe HDFN leading to intrauterine death. In a case report Anti-M has been 
associated with red cell aplasia in the newborn and hence it is suggested that Anti-M induced 
hemolysis may affect early erythroid stages, similar to the action of Anti-Kell. 
(43)(44)(45)(46)(47)(48)(49). Other MNS antibodies implicated in HDN are anti-Vw, anti-
Mur, anti-Hut, anti-Hil, anti-Mv, anti-Far, anti-s
D
, anti-Or, and anti-MUT. Antibodies to low 
incidence MNS antigens once identified in an antenatal woman must be looked upon with 
caution and may require closer monitoring, since there are no set critical titre levels 
documented for these.(50)(51)(52)(53) 
Maternal-fetal incompatibilities within the Duffy blood group system is an uncommon cause 
of HDN. The disease has usually been noted to be mild in nature. The Duffy antigens known 
to have caused maternal immunization and subsequent hemolytic disease are Fy
a
, Fy
b
, and 
Fy3, however the disease is milder.(54)(55)(56) 
There are several case reports and studies about alloimmunization leading to HDFN 
occurring due to other rarer antibodies. Some of these include: 
HDFN due Wra antigen from the Diego blood group system, which can occur even in the 
first pregnancy in newborn when a Wra negative mother is sensitized with a Wra positive 
neonate, inherited from the father. Severe HDFN with Wra antibodies have been described in 
literature and it is emphasized that these very rare antibodies should be suspected when the 
mother is IAT negative and the baby is positive for a DAT.(57) There is one more similar 
report highlighting a strong DAT positive in a newborn with mother being IAT negative 
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throughout pregnancy. However, at birth, using a collection of thawed red blood cells with 
rare phenotypes (private antigens), the presence of antibody anti-Wr(a) in the maternal serum 
was demonstrated. The antigen Wr(a) on the surface of the newborn and its biological father 
red blood cells was also confirmed. The concentration of IgG anti-Wr(a) on the baby’s red 
cells was demonstrated by the presence of the antibody anti-Wr(a) in the eluate. This case 
illustrates the difficulties to detect antibodies against private antigens on baby erythrocytes, 
responsible of hemolytic diseases of newborn. The standard red blood cell panels used for 
irregular antibodies screening tests in blood banks do not express generally these private 
antigens and therefore these may get missed during routine screening.(58) 
                   
            ALLOIMMUNIZATION DUE TO Rh ANTIBODIES:  
 
             Rh proteins are encoded by two separate genes encoded on short arm of chromosome 1, 
RHCE and RHD respectively. The RHCE gene encodes both the C/c and E/e membrane 
proteins associated with the Rh blood group system, while the RHD gene encodes for the D 
protein. The most significant of the Rh antigen is D antigen. The Rh negative phenotype 
results from deletion of the RHD gene on both chromosomes.  
                  Alloimmunization due to Rh antibodies leading to HDFN occurs due to incompatibility 
between mother and the fetus, when an Rh negative mother carries a Rh positive fetus. 
Hughes et al have suggested that the D antigen is a highly immunogenic antigen and can is 
likely to provoke an immune response in 80% of D-negative people transfused to 200ml of 
D-positive blood.(59) Similarly a leakage of fetal red cells into the maternal circulation 
provokes the maternal immune system leading to formation of antibodies to the newly 
exposed foreign antigens. The transplacental movement of these antibodies followed by 
attachment to respective antigens on fetal cells leads to red cell destruction characterizing 
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HDFN. Often the sensitizing event is the first pregnancy which goes uneventful and 
hemolysis of newborn is worse in the subsequent pregnancies. Following sensitization, re-
exposure to the antigen leads to an anamnestic  response increasing the maternal anti-D 
titres.(60) 
             Although it is often implicated that the child of a primiparous does not suffer HDFN, there is 
literature to support that Rh haemolytic disease though rare can occur in 1% cases during first 
pregnancy, and according to a study by Dajak et al. (2011) they observed severe HDFN in 
three primiparous patients who had experienced no sensitizing event such as abortion or any 
transfusion in the past.(27) (61) 
    
             Factors influencing Rh(D) HDFN include:(62) 
A. Size of feto-maternal haemorrhage: The fetal red cells that cross the placenta into 
maternal circulation during the third trimester is usually a small amount which is 
insufficient to stimulate antibody production in the mother. However during delivery, 
transplancental haemorrhage is commonly known to occur and fetal red cells varying 
from as less as 1ml to more than 10ml can cross into the maternal circulation leading to 
sensitization in upto 5-9% of pregnancies in Rh negative mothers. These mothers may 
form antibodies to the sensitizing event upto 6 months after the first delivery, and 
sometimes these antibodies may not be detectable initially but a fresh stimulus in the 
form of a subsequent pregnancy may increase it. When pregnancy with a second Rh (D) 
positive fetus occurs the fetal red cells may crossover through the placenta from as early 
as 24
th
 week of pregnancy further increasing the sensitization and provoking increased 
antibody titre levels, which can lead to HDFN.(62) However there are studies and case 
reports which have found anti-D associated HDFN even in primiparous women.(61) 
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B.  Parity: Parity has been found to correlate significantly with alloimmunization and risk 
of HDFN specially associated with second and third pregnancy.(63) 
C. Effect of ABO incompatibility between mother and fetus: ABO incompatibility has been 
shown to provide some protection from Rh HDFN. It is suggested that an existing ABO 
incompatibility between mother and fetus may destroy the Rh (D) positive fetal red cells 
as soon as they enter the maternal circulation, before they can initiate any sensitization 
in the mother. 
D. Zygosity of father: If the father is homozygous for a particular antigen to which the 
mother is sensitized then the fetus is at a definite risk of HDFN, however if the father is 
heterozygous the risk decreases by 50%. 
E. History of blood transfusion: The risk of sensitization of an Rh negative mother who 
previously received Rh positive blood is high, due to greater antigen load in transfusion 
as compared to a small transplacental leak. 
F. Medical Termination of pregnancy/abortion: Abortion or any interventional procedure 
during a pregnancy such as chorionic villous sampling can also be the sensitizing event 
leading to alloimmunzation in a woman, emphasizing the need for a detailed history.  
LABORATORY AND CLINICAL PERSPECTIVE FOR MOTHER AND 
NEWBORN: 
  Antenatal testing for alloimmunized women: 
The role of laboratory testing and fetal imaging studies is to guide the need for intrauterine 
transfusions, closer monitoring needs or early termination of pregnancy. However these tests 
have to be assessed in view of risk versus benefit for both mother and fetus. Antenatal 
assessment includes these basic steps: 
1. Detailed obstetric history: Bad obstetric history (previous hydrop fetalis/ still births/ 
early neonatal deaths) or evidence of other sensitizing events. 
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2. History of blood transfusion 
3. Grouping and typing 
4. Antibody screening/ Indirect antiglobulin test (IAT):  
       For an IAT, mother's serum is incubated with O pooled positive red cells at 37 degrees, 
allowing any antibodies present in the maternal serum to bind to the red cells. The cells 
are washed repeatedly to remove any free antibodies and Coomb’s reagent is added. The 
anti-Ig antibodies agglutinate red cells if they have maternal IgG antibodies bound to 
them. The indirect Coombs test, as the name suggests finds "indirect" evidence of 
maternal antibodies. 
5. Antibodies detected and identified, for its clinical implication. 
6. Father’s probable genotyping  
7. Antibody dependent cell mediated cytotoxicity (ADCC) test: The result of ADCC 
correlates with the severity of HDFN. 
8. Amniocentesis, when indicated. 
                       The major role of an apt blood bank is to identify the alloantibodies present, to 
determine their clinical significance and to perform titrations to assist the clinician make a 
decision on the requirement of an invasive fetal monitoring procedure. 
             During the first prenatal visit, ABO grouping and Rh typing must be performed on the 
mother’s sample. If the patient is found to be Rh negative with an initial antibody screen 
negative she needs to be given Rh prophylaxis. The antibody screen is a technique to detect 
IgG antibodies reactive at 37C and use separate screening cells representing all clinically 
important specificities. To avoid detection of IgM antibodies which do not cross the placenta, 
immediate spin and/or room temperature incubation should be omitted. A positive antibody 
screen must be followed up with appropriate antibody identification. Antibodies such as anti-
I, -P1, -Le
a
, -Le
b
, can be avoided whether IgM or IgG since these are poorly expressed of 
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fetal red cells and do not contribute to HDFN. Treatment of mother’s plasma with 
dithiothretiol (DTT) can be used to differentiate IgG and IgM since the latter is destroyed by 
it. If a clinically significant alloantibody is identified the next step would ideally involve 
establishing the father’s zygosity (homozygous or heterozygous) for the corresponding 
antigen. If the father is homozygous for the antigen then the fetus is definitely at risk of 
HDFN, and if the father is heterozygous then the genotyping of the fetus maybe determined 
by polymerase chain reaction (PCR) of sample obtained by amniocentesis, chorionic villous 
sampling or cordocentesis. However these tests are expensive with added risk to the fetus. 
               The antibody titration is a critical step in decision making for alloimmunized pregnant 
women. Different methods are used for the same, including saline AHG with sixty minute 
incubation at 37C (recommended by AABB), standard saline method, and gel technique. 
According to some literature the gel technique may result in titres in higher dilution resulting 
in inappropriate invasive management. It is recommended that a previously frozen serum 
sample must be run parallel with a current sample to minimize errors due to difference in 
technique or reading of results. The critical titre for anti-D, the level below which HDFN is 
unlikely has been found to be 16 or 32 according to studies.(64)(65) If titres are lower than 8 
except with respect to anti-K the pregnancy can be followed up with titres every 4 to 6 weeks 
until delivery. A difference of two dilutions is considered significant. If the titres approach 
critical levels and pregnancy is 18 weeks complete and invasive procedure such as 
ultrasound, Doppler imaging, amniocentesis or cordocentesis maybe used as per the clinical 
scenario. The critical titres levels are applied for all clinically significant antibodies, however 
for anti-K a titre as low as 8 can cause HDFN since these antigens are expressed even on 
early precursor red cells and can lead to fetal anaemia. 
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             Serological testing for newborn:  
            Investigation on a newborn suspected of HDFN broadly includes the following: 
1. ABO grouping 
2. Rh typing, including weak /partial D 
3. DAT: The principle steps of the test involves repeated washing of fetal red cells to 
remove unbound antibodies, followed by addition of the Coomb’s reagent (anti-Ig), 
which leads to agglutination of fetal red cells to by attaching to maternal antibodies 
which are already bound. Direct Coombs test is a synonym for DAT, the “direct” 
implies for the anti-IgG binding to the maternal antibodies coating fetal cells. 
In a study by Dinesh et al. they found DAT to have a sensitivity of 86% for the 
diagnosis of HDFN and it provided the first alert, even before jaundice for patients 
eventually requiring phototherapy.(66)  
4. Screening and identification of antibodies in cord serum 
5. Haemoglobin estimation on cord blood 
6. Cord blood bilirubin 
7. Hematological parameters 
 
             After birth, neonatal grouping and typing can be performed on cord blood sample, which 
needs adequate washing to avoid contamination for Wharton jelly. The D typing on cord cells 
maybe falsely negative if the fetal cells are coated heavily with anti-D due to prophylaxis 
rendered to the mother or due to repeated intrauterine transfusions. The DAT is one of the 
hallmarks for diagnosis of HDFN. It detects maternal IgG antibodies coating the surface of 
fetal red cells and the number of antibody molecules bound to the red cells determines the 
strength of the reaction. However the strength of the DAT has not found to correlate well 
with the severity of the disease. Infants may have a positive DAT with no signs of HDFN. A 
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positive DAT with negative maternal antibody screen may occur due to ABO antibodies or 
alloimmunization to a low prevalence antigen. 
CLINICAL MANIFESTATIONS OF HDFN:  
 
The clinical manifestations of HDFN may vary greatly depending on the various factors 
discussed above and finally the strength of the immune response. The disease may only lead 
to mild anemia diagnosed on the basis of laboratory parameters, to severe anemia leading to 
hepato-splenomegaly as a result of compensatory erythropoietic tissue hyperplasia. In case 
the anemia surpasses the compensatory mechanisms it leads to pallor, signs of cardiac failure 
(cardiomagaly and respiratory distress), anasarca and shock. “Hydrops fetalis” is 
characterized by accumulation of excessive fluid in two or more fetal compartments, such as 
skin, pleura, pericardium, peritoneum. The severity of hydrops is dependent on the  
hypoalbuminemia, which occurs due to the liver dysfunction and also due to right heart 
failure leading to edema and ascites. In the case that there is a failure to initiate effective 
ventilation at birth due to pleural effusion or pulmonary edema it may lead to birth asphyxia. 
 Thrombocytopenia may also be a manifestation of HDFN or occur as a result of 
disseminated intravascular coagulation and may lead to bleeding manifestations such as 
petechiae and purpuras. Jaundice which is the other significant and common finding, is 
usually evident on the first day of birth itself and the amniotic fluid may also be stained by 
bilirubin if the hemolysis is severe enough to exhaust the placenta’s capacity to clear it. The 
levels of unconjugated bilirubin may rise rapidly and put the baby at risk of developing 
encepahalopathy. These newborns may also suffer from hypoglycaemia and acidosis due to 
related hyperinsulinemia and hypertrophy of the islet cells of pancreatic tissues.   
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DIAGNOSIS OF ANEMIA, HEMOLYSIS AND HYDROP FETALIS:  
 Fetal monitoring is used to detect the early features of HDFN or clinical features suspicious 
of hydrops fetalis, which can be associated with high risk of mortality and to determine the 
needed for transfusion requirements. This is accomplished by three methods: 
-Doppler ultrasonography 
-Amniocentesis 
-Fetal blood sampling eg.Cordocentesis 
DOPPLER ULTRASONOGRAPHY:  It is a much preferred non-invasive method which has 
largely replaced the invasive aminocentesis test. It was first proposed by Mari et al. and 
measures blood flow velocity. Fetal anemia results in increased cardiac output and decreased 
viscosity which increases the blood flow. Fetal middle cerebral artery is commonly chosen 
for study purpose since can be used with minimal angle of insonation. It was established by 
the pioneers of this method through studies on 265 normal fetus, that values of 0.84 to 
0.65Mom corresponded to mild anemia, 0.65 to 0.55Mom to moderate anemia for the 
gestational age and severe anemia was less than 0.55 Mom. Following this, more than 
thousand fetus at risk of HDFN with alloimmunized mothers were evaluated prospectively 
and a value of greater than 1.5Mom was found to correlate with severe anemia.(67) It is 
therefore considered critical for establishing need for a further fetal blood sampling. The 
measurement of middle cerebral artery peak systolic velocity (MCA-PSV) has been shown to 
correlate with the severity of anemia and predict the need for invasive procedures, such as 
intra uterine red cell transfusion. It has specially been found to correlate well with diagnosing 
moderate to severe anemia in the fetus.(65) 
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             AMNIOCENTESIS: Before the development of colour Doppler ultrasonography, the severity 
of HDFN was monitored by serial ultrasound guided amniocentesis, to follow the bilirubin 
levels in amniotic fluid by spectral analysis. The aspirated fluid is tested by a scanning 
spectrophotometer at 450nm optical density (▲OD 450), to measure bilirubin levels as an 
indicator for degree of hemolysis. The result is plotted on a graph according to gestational 
age, however it is useful only after 27 weeks of gestation. This method was first clinically 
introduced by Liley in 1961, who proposed a graph divided into three zones: top (zone 3) 
with the highest value, indicating most severe disease, needing intrauterine transfusion if less 
than 32 weeks into the pregnancy or termination of pregnancy depending on the maturity of 
the fetus. Middle area (zone 2) indicated a moderately affected fetus, and may need exchange 
transfusion following delivery and the lowest (zone 3) was for mild form of disease in which 
the newborn may or may not be affected. 
               Amniocentesis is usually carried out between 28 and 32 weeks of pregnancy, and can be 
repeated after two weeks. (68)The optical density of amniotic fluid (at 450-460nm) is about 
0.05 at the 30
th
 week of pregnancy, and falls to about 0.02 near term. The OD readings can 
help estimate the risk of HDFN and take decisions on the need for intrauterine transfusion or 
early termination of pregnancy.(62)(69) The risk of fetal loss per procedure is 0.25-1% and it 
also adds to the risk of increased fetomaternal haemorrhage.(70) 
              A graph for lower gestational age was proposed by Queenan et al, and involves four zones 
instead of the earlier three. 
              Fetal blood sampling includes various methods of testing such as cordocentesis, 
funipuncture and these involve direct access to the fetal circulation. These are used to obtain 
fetal blood samples for crucial tests such as DAT, hematocrit levels and for estimation of 
fetal acidosis. Though still considered the gold standard test for assessing fetal anemia 
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however, it is associated with 1-2% risk of fetal loss during procedure. (68) A hematocrit of 
less than 30% is a strong indicator for the need of intrauterine transfusion.(65)  
             O blood group, RhD-negative, leukodepleted irradiated blood to prevent risk of transfusion 
associated graft versus host disease is the standard requirement for an intrauterine 
transfusion. The purpose of intrauterine transfusion is to maintain the fetal hemoglobin value 
at more than 9 g/dL.(65) 
             
HEMOLYSIS AND IgG SUBTYPES: 
Rate of hemolysis and severity of HDFN is determined by various factors such as, IgG 
subclass, amount of antibody and the number of antigenic sites on red cells .One factor that 
contributes to the degree of hemolysis and has not been evaluated enough in the Indian 
context is the IgG subclass. IgG is the major immunoglobulin in normal human serum. Four 
human subclasses of the IgG molecule can be differentiated, IgG1, IgG2, IgG3 and IgG4, of 
which IgG1 is predominant. Although all 4 subclasses are able to cross the placenta, types 1 
and 3 bind to the Fc receptor of phagocytic cells with greater affinity than do types 2 and 4. 
Hemolysis is therefore expected to occur to a greater extent in association with the 
former.(28),(32) 
According to studies by Garty et al. there is a close linear relationship between placental 
transfer of each of the IgG subclass and gestational age, and although all the IgG subclasses 
can cross the human placenta, their transport is not uniform: the transport of IgGl and IgG4 is 
more efficient than that of IgG3 and IgG2, it is noted to be least for IgG2 antibodies. Reduced 
passage of IgG2 from mother to fetus was reported earlier by Wang et al. and Hay et al., 
whereas Pitcher-Wilmott et al. and Morell et al. reported similar passages for all four 
subclasses.(71) There is no satisfactory explanation for these discrepant results in studies. 
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Despite these findings it has been clearly demonstrated that the subclasses IgG1 and IgG3 are 
more efficient at causing hemolysis than IgG2 and IgG4.It has been observed that IgG1 
shows greater affinity to the receptors on placental tissue than IgG2. Morell at al. and Schur 
et al. observed as early as in 1971, documented that among the IgG1 and IgG3 subclasses it 
was the former that rose at an earlier stage of gestation. (28) 
There is varied literature on the opinion of severity of HDFN in relation to IgG1 and IgG3. 
While some authors have shown that it is mainly IgG1 antibody that causes severe disease, 
others have suggested that severe HDFN occurs when both IgG1 and IgG3 are present in the 
maternal serum. However the respective contribution of IgG1 and IgG3 in the pathogenesis is 
still unclear.(72)(4)(73) 
According to a study by Iyer et al. conducted in KEM hospital, Mumbai, they found that in 
107 Rh (D) immunized antenatal women screened between 34
th
 and 36
th
 week of pregnancy 
they found all the four IgG subtypes detected in the sera using polyclonal IgG subtype 
specific reagent, however IgG1 and IgG3 were the predominant classes. They observed that 
IgG3 anti-D was usually found in low titre patients, and at the same titre levels IgG1 alone 
caused more severe HDFN than IgG3 alone. HDFN was found to be most severe when IgG1 
and IgG3 co-existed and there was highest risk of having a still born (IgG1 +IgG3 34.8%, 
IgG1 19.2% and IgG3 15.4%).(74) 
With similar findings is another study conducted in Canada, by Pollock et al. published in 
Vox Sanuinis in 1990, which examined the influence of IgG subclasses and severity of 
HDFN. They found that disease was severe in 19 of 32 cases with only IgG1, 40 of 63 cases 
with both IgG1 and IgG3 and 0 of 3 with only IgG3 detected. Therefore when both IgG1 and 
IgG3 existed disease was most severe than IgG1 alone.(4)    
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According to a major study by Lamin et al published in 2002, correlating IgG1 and IgG3 
anti-D in maternal serum with severity of disease, they found HDFN correlating with IgG1 
anti-D for several reasons. Primarily they found, a negative correlation between infant’s 
hematocrit (Hct) and IgG1 anti-D concentrations in maternal serum, in contrast, there was a 
positive correlation between infant’s Hct and the amount of IgG3 anti-D bound to infant’s red 
cells. Secondly, a higher concentration of IgG1 anti-D in maternal sera was observed in the 
26 cases of HDN necessitating intrauterine transfusion (IUT) than in the 14 cases of HDN 
requiring post natal transfusion (PNT) alone. In contrast, on infants’ RBCs, the amount of 
IgG3 anti-D was significantly higher in the 14 cases of HDN necessitating only PNT than in 
the 26 cases necessitating IUT. Lastly, in the 12 cases of HDN that required IUT and in 
which the maternal serum had a proportion of IgG3 anti-D above 5 percent, it was found that 
the highest proportions of IgG3 anti-D were associated with the highest Hcts and with later 
times of gestation for the first IUT. Therefore, the quantitative analysis of IgG and IgG 
subclasses of anti-D in 40 cases of HDN helped to conclude that the amount of anti-D fixed 
on infants’ RBCs increases with the concentration of maternal anti-D but that the ratio of the 
concentration of anti-D on infants’ RBCs to that in maternal serum diminishes as the 
maternal concentration increases. In addition, the proportion of IgG3 anti-D on infants’ RBCs 
is about three times lower than in maternal sera. Finally, correlations between anti-D IgG 
subclass concentrations (and percentages) in maternal serum (and on infants’ RBCs) with the 
intensity of fetal anemia suggested that IgG1 rather than IgG3 played a more important role 
in the pathogenesis of this condition.(75) 
    Most of the studies have focused on Rh hemolytic disease, and found that infants who are 
sensitized primarily with IgG1 are more likely to be severely affected than their IgG3 
predominant counterparts. IgG3, however, may also be associated with rapid postnatal rise of 
serum bilirubin concentrations. Combination of IgG1 and IgG3 seemed to result in the most 
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severe form of hemolytic disease.
 
It has been suggested that identification of IgG subclasses 
may yield prognostic information regarding the development of hemolysis and 
hyperbilirubinemia. 
However there is limited literature looking at the significance of IgG subclasses in correlation 
with other antibodies which are known to cause HDFN. According to Thomas et al., (1995), 
they studied some of the other clinically significant antibodies encountered in a series of 
antenatal women, which included E, Fya, Jka and S. According to this study IgG1 and IgG3 
accounted for greater than 50% of the antibodies subclass distribution in 5 cases that resulted 
in HDFN. Although no conclusive result could be documented due to a small sample size.(73) 
Though standardization of these tests is difficult, there are studies which have explored 
ELISA, Flow cytometry and gel centrifugation technique to categorize IgG 
subclasses.(76)(77) 
There is a study by Ahaded et al.(2002) which looked at the IgG sublclass distribution in the 
second most important alloantibody group cauing HDFN, that is the Kell system. They used 
ELISA to quantitate anti-K (KEL1) IgG subclasses in serum of severely alloimmunized 
women and found that in comparison to the anti-D system, 95% of anti-K antibody was IgG1 
subclass. There were only small amounts of IgG2, IgG3 and IgG4. This is in contrast to anti-
D group where both IgG1 and IgG3 have been found to be significant. (78) 
 
Column Agglutination technique: Lapierre et al, was the first to describe this 
technology which aimed to standardise red blood cell agglutination reactions and help in 
uniform interpretation of results. It involves trapping the agglutinates, which can be simply 
read and graded by naked eye.  
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One column usually consists of six special microtubes containing a dextran gel matrix. Red 
and serum or red cells alone depending on the test being carried out is added into the 
microtubes in a specific concentration as per manufacturer and test protocol, followed by 
incubation when necessary, and then centrifuged under stringently controlled parameters. The 
gel contained in each of the microtubes acts as a sieve, to trap the antigen antibody 
complexes formed, while the unagglutinated red blood cells form a pellet at the bottom of the 
tube. The gel in the microtubes may be neutral or contain specific reagents as per the test 
being carried out.(6) 
GUIDELINES FOR ANTIBODY SCREENING AND IMMUNOPROHPHYLACTIC 
MEASURES: 
 Recommendations from various bodies state that all women during their first antenatal visit 
must have a blood grouping and antibody screening performed. It has been reported that 
1.5%–2% of pregnant women show atypical blood group sensitization.(79) There is however 
a mixed opinion on the clinical significance of a repeat anti-D antibody screen at 28 week of 
gestation. Clinicians who are of the view  that a repeat testing should be carried out at 28 
week suggest that there is the potential advantage to identify about 0.18% or fewer women 
particularly Rh-negative who become alloimmunized after their first antenatal screen possibly 
as a result of potential sensitizing event occurring after the first antenatal visit and may 
otherwise go undiagnosed until too late.(80) Presently antibody screening is recommended 
for all antenatal women at 12 weeks of gestation or the first antenatal visit. Those found to be 
Rh positive and with a negative antibody screen, undergo a repeat screening at 28 weeks and 
no further action needed if same results continue. Those found to be Rh negative with a 
negative antibody screen at 12 weeks, are retested at 28 weeks and if remain negative are 
provided routine Anti-D prophylaxis. If the baby is found to be Rh positive, Rh prophylaxis 
post delivery is given and feto-maternal haemorrhage quantified. 
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For mothers found to have a positive antibody screen at initial check up, antibody 
identification and titration is recommended. Titres are done every four weeks until 28 week 
of gestation, followed by once every two weeks till delivery.  A rising trend in titres (>16) or 
a jump of more than two dilutions requires close follow up which may include Doppler test, 
intrauterine transfusion or any early termination of pregnancy.(81)  
Rh immunophrophylaxis rarely leads to  Anti-D titres levels of more than 4, which is not 
considered to be clinically sufficient to cause fetal red cell hemolysis.(69)(65) The half life of 
Rh immunoglobulin is approximately 24 days, therefore if received at 28 weeks, 15-20% 
women receiving it will have very low titres of anti-D (Titres of about 2 to 4), detectable at 
time of labour. 
RH PRPHYLAXIS RECOMMENDATIONS: according to the American Society of Clinical 
Pathology the testing for unexpected antibody should be carried out before a prophylactic 
antenatal anti-D is given to Rh-negative pregnant women. Repeat testing is not needed if the 
Rh negative status is documented twice.(82) Since 1990, with the advent of Rh immuno-
prophylaxis in the clinical management there has been a noticeable reduction in mortality due 
to HDFN. A further reduction was brought about by introducing prophylaxis during the third 
trimester of pregnancy.(83) These findings contributed to the National Institute for Clinical 
Excellence (NICE) recommendation that all D-negative pregnant women who do not have 
immune anti-D should be offered anti-D immunoglobulin routinely during the third trimester 
of pregnancy.(84) Initially anti-D immunoglobulin was administered antenatal only when a 
sensitizing event occurred that could be associated with a feto-maternal hemorrhage.  
According to BCSH guidelines a sensitizing event could include following events:  
 Amniocentesis  
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 Cordocentesis  
 Any in-utero therapeutic interventions or measures (e.g. intrauterine transfusion)  
 Chorionic villus sampling  
 Ectopic pregnancy  
 Ante partum haemorrhage (APH)  
 External cephalic version  
 Termination of pregnancy  
 Intrauterine death  
 Miscarriage  
 Fall / abdominal trauma  
NICE recommends that Rh immune-prophylaxis should be offered as two doses of anti-D 
immunoglobulin of 500 IU at 28 and 34 weeks respectively or as a single dose of 1500 IU 
dose between 28 and 30 weeks. There is no clear evidence based guidelines comparing the 
advantage or efficacy of single dose prophylaxis to divided dose.(85) 
    It is part of modern day antenatal care to offer all RhD-negative pregnant women an anti-
RhD immunoglobulin IgG injection at about 28 weeks’ gestation with or without a booster at 
34 weeks’ gestation. This reduces the effect of the vast majority of sensitizing events which 
mostly occur after 28 weeks’ gestation. Anti-RhD immunoglobulin is also given to all Rh-
negative women immediately after or within a span of 72 hours after pregnancy, since the 
delivery could be the major sensitizing event. The prophylactic immunoglobulin rarely leads 
to titres of anti-D usually greater than four, which should not cause HDFN. (69) A titre of 16 
or above is considered critical for all alloantibodies, except Kell, in which a titre of more than 
eight can lead to severe suppression of fetal hematopoiesis.(86)  
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The mechanism of action of anti-D immunoglobulin (Ig) is not very clearly understood. It is 
known to suppress the immune response activity of an RhD-negative mother, when exposed 
to RhD-positive fetal cells. The suggested mechanisms of action include, primarily, Anti-D Ig 
induces rapid clearance of the RhD-positive fetal cells, interfering with the presentation of Rh 
antigens by dendritic cells and macrophages; secondly, it also suppresses the RhD antibody 
production by the reactive B cells. 
According to a major work presented by Koelewijin et al.which looked at risk factors for Rh 
sensitization and the pit falls of prophylaxis measures. They interestingly found twin 
pregnancy as a risk factor following univariate analysis. Non-spontaneous deliveries which 
included both caesarean section and assisted vaginal deliveries were also seen as a risk factor 
for increased FMH, exceeding the amount of fetal cells that could be neutralised by a single 
dose of anti-D Ig of 1000 iu (200 Ig) as recommended in some guidelines. Most national 
guidelines also support the use of a Kleihauer–Betke test as a routine modality for 
quantifying the FMH after caesarean section to guide the accurate dosage of postnatal anti-D 
Ig.(87)  However it has not been universally supported or applied since various studies have 
shown different results for the sensitivity and specificity of the test, probably due to manual 
performance and factors such as small amount of FMH which may not be picked up by this 
method.  
   The Kleihauer–Betke test is performed in most hospitals specially in a developing country 
by the manual method with stained blood smears, however more sensitive and accurate 
results may be obtained using a flow cytometry- based method and the technical merit and 
validation of the used method may be of influence on test performance. In the conventional 
method  the fetal blood loss into the maternal intraperitoneal cavity, may not be detectable by 
the Kleihauer–Betke test, which may lead to further RhD immunisation, not covered by 
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routine prophylaxis, since 300ug is suppresses alloimmunization by 30ml of fetal whole 
blood(69). 
Kleihauer Betke test works on the principle of resistance of fetal red cell haemoglobin to acid 
treatment. A thin smear of maternal blood is made, which is treated with acid, rinsed and 
counterstained, and finally read under the microscope. The maternal red cells appear as 
“ghosts” and the fetal red cells appear darker pink, as depicted in Fig 2.  
The FMH is estimated using a simple formula proposed first by Mollison in 1962, which was 
based on three assumptions: (88) 
 The red cell volume in the other is estimated to be approximately 1800mL 
 Fetal cells are estimated to be 22% larger than maternal red cells 
 Only 92% of fetal cells are found to stain darkly 
 
 
Fig 2: Acid elution technique for Kleihauer Betke test and the formula to calculate feto-
maternal haemorrhage. 
Feto-maternal haemorrhage calculation:
Number of fetal red cells per high power field              /   2400
Number of maternal red cells per high power fiels
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The post maturity of fetus also contributes as a risk factor in HDFN susceptible pregnancies 
since, in addition to the prolonged affect of the to the  immunogenic effect of fetal red cells in 
the maternal circulation and as stated by some studies the drop in levels of anti-D Ig with 
time. There are studies which have shown undetectable levels of anti-D Ig more than 12 
weeks after administration, even when a 300 lg of anti-D Ig was administered in a single 
dose. This emphasizes the fact that, anti-D Ig levels may drop too low if a pregnancy exceeds 
42 weeks increasing the risk of sensitization.(87) 
Despite all these stringent measures to reduce risk of sensitization and, the threat of HDFN 
continues to persist. It has been found that in present scenario one of the most important 
causes of anti-D antibodies sensitization is due to a mild event during the pregnancy itself, 
best explained as a no noticeable overt sensitising event. A late sensitizing event, during the 
third trimester of a first pregnancy, has been found to be responsible for 18–27% of cases. 
Sensitization events during second or subsequent pregnancies may account for a similar 
proportion of cases. However clinically it is not feasible to distinguish a late sensitising event 
from failure of prophylaxis at the end of the preceding pregnancy as the precipitating 
event.(89) 
 
INDIAN RECOMMENDATIONS FOR PROPHYLAXIS: The Federation of Obstetrical and 
Gynaecological Societies of India (FOGSI), recommendations state that Rh 
immunoprophylaxis should include:  a dose of 50-100 μg of anti-D Ig in case of any 
sensitizing event in the first trimester. A further routine antenatal prophylaxis in the second 
trimester is advocated, that includes all women tested at registration and 28 weeks. They 
should either be administered 100μg at 28 and 32 weeks each respectively or a single dose of 
300μg at 28weeks and followed by a post partum dose of 300 μg for all pregnancies within 
72 hours. Women with a weak D identified need not receive Anti-D. 
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THERAPEUTIC MEASURES FOR NEWBORN: 
 
Management of HDFN is broadly categorized into two- the antenatal and post-natal aspect. 
The management of the newborn is basically described to be supportive and 
symptomatic.(90) Most previous studies have categorized the disease on the basis of 
combination of DAT result, hemolysis seen and the treatment modality needed.(4,74)(90) 
While intrauterine transfusion is the corner stone of antenatal management, post-natal 
initially consisted primarily of phototherapy and exchange transfusion, but in present day IV 
immunoglobulin also plays a major role. Phototherapy was initially started in 1956, and since 
then has come a long way in managing jaundice in newborns. It had also lead to a decline in 
frequency of exchange transfusion and mortality related to it.(91, 92)  
Phototherapy: Despite phototherapy becoming such an integral part of management of 
jaundiced newborns, there is limited evidence based guidelines for its dosing. The 
conventional phototherapy to start with utilized a source of white light, exposing the 
newborns to 7-10μW/cm2/nm. It helped in a decline of 6-20% of serum bilirubin in the initial 
twenty four hours. However presently there are much more intensive phototherapy methods 
available. These basically include using blue lamps and placing the baby at a distance of not 
more than 10cm and generating a spectral irradiance of greater than 50μW/cm2/nm. Double 
surface phototherapy is also used to increase the surface area exposed to the irradiance with 
the application of fibre-optic pads these are routinely used in specialized neonatal set ups 
these days. (93)  
Exchange transfusion: It comes into play when phototherapy has not been effective and 
there are recommendations for its appropriate use elaborated by the American Academy of 
Paediatrics(AAP).(94) In addition to removing excess bilirubin it also contributes in 
removing maternal antibodies in the circulation, and reducing chances of further on-going 
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hemolysis. It is done with double volume (160ml/kg) irradiated, leukocyte depleted 
compatible blood, ideally negative for cytomegalovirus (CMV) via an intravenous catheter 
inserted in the umbilical vein. Exchange transfusion has its independent hazards and is 
associated with a high risk of procedure related morbidity. The requirement of exchange 
transfusion in HDFN may vary from 20 to 70%, and while in a study by Birchenall et al. they 
found the rate of transfusion as high as 37%, another study by Loporiore et al. found it 15-
17% and managed more cases with intensive phototherapy and top up transfusion.(95)(96) 
There are no international guidelines for management of HDFN using uniform triggers or 
thresholds for transfusion requirements. This is mostly because of the comparatively low 
prevalence of the disease, because of which large evidence based studies have been limited. 
This has lead to lack of literature to compare transfusion requirements and to assess 
variability in regard to transfusion thresholds, volumes, products and different outcome 
measures.  
There have been significant steps made in antenatal and postnatal management strategies 
since the journey began to overcome HDFN. New diagnostic techniques, monitoring tools 
and management options are constantly under investigation. While intravenous 
immunoglobulin has also been recommended by AAP in infants in whom bilirubin is on the 
rise despite intensive phototherapy the evidence is still inconclusive according to some 
studies. There is also research work going on looking at erythropoietin to stimulate fetal 
hematopoiesis in HDFN.(97)(94) 
 Against the complex scenario of HDFN, it’s variable clinical presentation and differing 
levels of management, it would add great clinical value to know if an antibody when 
identified is clinically more likely to cause disease or not. Literature from the west suggests 
that the IgG1 IgG3 subtype testing offers this value addition. This study was performed to 
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assess prevalence of IgG1 and IgG3 subtypes in alloimmunized antenatal women in a tertiary 
care centre in South India using the DAT IgG1/IgG3 card test on the column agglutination 
platform.  In addition we aimed to correlate severity of disease with the test results to see if 
this could be used to prognosticate severity of HDFN, This would allow for deciding 
frequency of antenatal follow up, antenatal intervention and proactive management of the 
newborn. Being a simple test on a platform familiar to most transfusion personnel, if found to 
be clinically relevant, this could easily be implemented if required. 
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METHODS AND MATERIAL 
 
SETTING:  
1. The study was conducted in Christian Medical College, Vellore, Tamil Nadu.  It is a 
3000 bed teaching hospital providing tertiary medical care to the residents of Vellore 
and surrounding districts of Tamil Nadu, Andhra Pradesh and Kerala.  It also serves 
as a referral centre for patients from rest of India and South East Asia. This 
observational cohort study was carried out in the Department of Transfusion Medicine 
and Immunohematology (Blood bank), with the department of Obstetrics and 
Neonatology.  
2. The primary objective of this study was to find out the prevalence of IgG subtypes 
(IgG1 and IgG3) in antenatal women in South India. It required inclusion of all 
antenatal women identified to be alloimmunized at the blood bank during a routine 
antenatal check up irrespective of period of gestation, over a period of one and a half 
year, spanning between, January 2013 – July 2014.  
3. The second objective of the study was to correlate IgG subtypes and severity of 
HDFN. Women included in the first part of the study were followed up through their 
pregnancy to observe the outcome. The blood group and DAT done on the newborn’s 
sample was used to label “HDFN or NO HDFN” and severity was graded into mild/ 
moderate/ severe based on treatment required. 
4. This study involved a novel test for the blood bank, IgG subtyping by column 
agglutination technique to identify the IgG subclass (IgG1 or IgG3) in the maternal 
serum. 
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PARTICIPANTS:   
 
All antenatal alloimmunized women identified during a routine antenatal check up to have a 
positive antibody screening test were enrolled as study participants. This was irrespective of 
the antibody identified, titre levels or parity 
Inclusion criteria for the study: 
                               1. All alloimmunized Rh negative antenatal women, irrespective of parity. 
                   2. All antenatal women with antibody screen positivity 
 
Lost to follow up: Antenatal women enrolled in the study during an antenatal check up, but 
who did not deliver in Christian Medical College and Hospital were categorised as lost to 
follow up. They were included only for the calculation for IgG subtype, but not analysed 
further in correlation with HDFN. 
METHODOLOGY:  
All antenatal women during their antenatal visit have a blood grouping and typing and 
antibody screen performed as per routine protocol. Those found to be alloimmunized by 
virtue of having a positive antibody screen were recruited for this study, irrespective of 
period of gestation. (Fig 3) These samples were further evaluated as per usual protocol to 
identify the antibody specificity. The serum sample was then stored for processing the same 
for IgG subclass testing.  
Mothers identified to have a positive antibody screen were then followed up with help of 
support departments which included Medical records and Neonatology. Clinical details and 
relevant laboratory results were accessed from the clinical work station of the hospital, both 
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for the mother and subsequently for the baby. The course and outcome of the pregnancy was 
followed up in consultation with neonatology and details from the clinical workstation 
The newborn was evaluated for presence or absence of HDFN. If present, severity was 
assessed. Classification of hemolysis and severity of disease was done in consultation with 
the department of Neonatology into one of three grades - namely Mild/ Moderate/ Severe 
HDFN. This was based on therapeutic interventions as per guidelines laid down by the 
Department of Neonatology for this study, since modalities of therapy are decided based on 
severity of disease. There were no clear guidelines available to categorize the disease. In a 
previous study from India, the severity of disease was categorized on the basis of still birth, 
live but requiring exchange transfusion and live and not requiring exchange transfusion, 
however the criteria for exchange transfusion was based on haemoglobin and bilirubin and 
varied between clinicians.(74) Another study from the west has used haemoglobin, bilirubin, 
treatment modality and outcome of the baby as the criteria for classifying severity.(4) 
SAMPLE PROCESSING: 
Following blood grouping, antibody screening, antibody identification and titration done as 
per routine protocol or requirement, all samples which had been collected in EDTA 
vacutainers were centrifuged at 3000 rpm for 3minutes and plasma separated and stored in 
eppendorf tubes at -70 degreesC, until a later date to perform the IgG subtyping, by the 
column agglutination technique using ID card “DAT IgG1/IgG3” DiaMed GmbH 1785 
Cressier FR Switzerland (BIO-RAD). 
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Fig 3: Algorithm to demonstrate the methodology of this study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All Antenatal women on routine 
antenatal check up from the OPD or 
referred from outside, found to be 
alloimmunized based on the sample 
sent to blood bank for blood 
grouping and antibody screening 
-Blood 
grouping/typing 
-Antibody screening 
-Indirect 
Antiglobulin test 
-Antibody 
identification 
Titre (when 
documented) 
 
 
Antibody 
identification 
 
 
IgG subtyping 
 
 
Pregnancy followed up. Outcome documented by 
collecting information from medical records and work 
station Baby’s parameters were also followed up. 
The newborn was monitored after birth upto hospital 
stay and subsequent interventions were documented 
through records 
Disease was categorized into 
No/Mild/Moderate/Severe HDFN 
with help from the Neonatology 
department based on DAT result 
and choice of treatment 
modalities 
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EXPECTED OUTCOMES: 
           Primary: 
1. Classify IgG subtypes (IgG1 and IgG3) 
2. Outcome variable, namely HDFN present or absent 
3. Severity of HDFN into Mild/Moderate/Severe 
DATA COLLECTION and SOURCE OF DATA: 
A. Data of the mother: 
Demographic 
Personal:  
1. Blood group 
2. Period of gestation  
3. Obstetric history 
4. History of transfusion 
5. Indirect Antiglobulin test result 
6. Antibody identified 
7. Titre levels 
8. Outcome of pregnancy 
B. Baby’s data: 
1. Live/ Still birth/ Intrauterine death 
2. Preterm/ Term/ Post-term 
3. Gender 
4. Weight at birth 
5. Blood group 
6. Direct antiglobulin test  
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7. Cord blood haemoglobin (if done) 
8. Cord blood bilirubin (if done) 
9. Features of HDFN 
a. Jaundice 
b. Pleural effusion 
c. Ascites 
d. Hypoalbuminemia 
e. Acidosis 
f. Hydrops 
g. Kernicterus 
h. Coagulopathies 
i. Sepsis 
10. Haemoglobin (monitored over hospital stay; lowest level documented) 
11. Bilirubin (monitored over hospital stay; highest level documented) 
12. Reticulocyte count (monitored over hospital stay; highest level documented) 
13. Treatment required- including admission to the Neonatal intensive care unit 
14. Treatment details: 
a. Only observation and serial monitoring of parameters 
b. Phototherapy 
c. Exchange transfusion 
d. Intrauterine transfusion 
e. Any top-up blood/component transfusion 
f. None 
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We analyzed the above mentioned data from medical records and work station. The HDFN 
was graded according to guidelines set with help from Department of Neonatology. 
HDFN was characterized into Not present /Mild/ Moderate and Severe 
 
1. No HDFN- DAT negative  
2. Mild- Requiring observation only (DAT positive) 
3. Moderate- DAT positive, requiring phototherapy (Single/Double surface) 
4. Severe-DAT positive, requiring Intrauterine transfusion/ exchange transfusion/ blood 
transfusion/perinatal death 
Tests done in the blood bank:  
 
A.    On mother’s plasma sample:  
1. Blood grouping and Rh typing 
2. Antibody screen/ Indirect Coomb’s test 
3. Antibody identification using the three cell panel and eleven cell panel, using  
column agglutination technique 
4. IgG subtyping (IgG1 and IgG3) using Column agglutination technique, finding 
high (1:100) and low titres (1:1) for each respectively. 
5. Antibody titration was done when requested by the clinician 
B. On newborns’ sample: 
1. Blood grouping and Rh typing 
2. Direct Antiglobulin test 
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COLUMN AGGUTINATION TECHNOLOGY:  It is a commonly used platform in blood 
banks presently, and it uses gel or glass beads to trap agglutinated red cells following an 
antigen antibody reaction. Test can be performed on this platform manually or by 
automated means, which allow for processing multiple samples at the same time. CAT 
as it is commonly known as, can be used for tests like blood grouping, antibody 
screening, DAT, IAT and cross-matching. Antigens expressed on the red cells interact 
with antibodies in the chambers at the top of a column, and after proper incubation and 
centrifugation as recommended by the manufacturer, the test can be interpreted. The 
agglutinated red cells remain at the top, and are read as a positive reaction, while the 
free red cells are forced through the column to the bottom and read as negative. This 
forms the principle of many tests carried out via this platform in our blood bank. 
 
STANDARD OPERATING PROCEDURE: 
 
A. IgG1 and IgG3 SUBTYPING: 
Principle: The risk of hemolysis in HDFN depends on the amount of IgG coated on the red 
cells as well as on the IgG subclasses involved. To induce phagocytosis it is suggested that 
approximately 1000-4000 IgG1 molecules or 135-500 IgG3 molecules must coat the red 
cells. Therefore it is not only important to identify the presence of these subclasses but may 
require an estimation of the titre levels to comprehend its clinical significance. 
Principle: The ID-Card “DAT IgG1/IgG3” has two dilutions (1:1 and 1:100) of the both 
subclasses and works on the principle of CAT. 
 Materials: ID-card with 6 columns as in Fig 4 (having four microtubes for IgG 1 and IgG3 
in two dilutions each, a negative control well, and a positive control well), ID-Dia cell (0.8%) 
suspension, Pipettes, Tips, Incubator and Centrifuge. 
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Procedure: 
1. Serum or plasma sample stored previously at -70degress C is thawed to room 
temperature and centrifuged at 1500g for ten minutes to avoid fibrin residues which 
can interfere with reaction pattern. 
2. Label the ID-card with appropriate patient hospital/identity number. 
3. Remove aluminium foil, holding the card in upright position. 
4. Pipette 50μl of ID-DiaCell into each microtube. 
5. Add 25μl of patient plasma/serum to each microtube. 
6. Incubate the card for 15mintues at 37degreesC in the incubator. 
7. Centrifuge the card for ten minutes. 
8. Interpret and record the agglutination reaction. 
If the positive or negative controls failed the test was considered un-interpretable.  The test 
was repeated for these patients with DTT (0.01N in 1:1 concentration, following incubation 
for 30min at 37 degrees) treated plasma and read when the control came negative. 
Interpretation:   
A. Positive: Agglutinated cells form a red line on the surface of the gel (strong reaction) 
or the agglutinates tend to disperse in the gel in a weaker reaction.  
           Negative: Compact button of cells at the bottom of the microtube. 
A positive reaction with the 1:1 dilution has a sensitivity of approximately 1000 Ig1 
molecules and 125 anti-IgG3 molecules respectively. A positive reaction in 1:100 
dilution is indicative of a higher strength of antibodies in the plasma. 
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Fig 4: The DAT IgG1/IgG3 card  
 
DAT IgG1/IgG3 card consists of six microtubes as depicted in the figure above. The first two 
tubes are for detection of IgG1 in titres of 1:1 and 1:100 respectively. The next two wells are 
coated for IgG3 in 1:1 and 1:100 titre. The fifth tube acts as the negative control for the test, 
and should be negative for the test to be interpretable. The last well is for overall IgG 1:10 
(IAT) which acts as the positive control for the test.  
 
 
DAT IgG1/IgG3 ID-Card DiaMed (BIO-RAD)
Positive 
Control 
Negative 
Control 
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Fig 5: Test results on the card 
 
 
 
Fig 6: Test results on card 
Table 2: Result interpretation on the DAT IgG1/IgG3 card 
IgG1 H+ IgG3 H: Positive,
Control: Negative
High titres of both IgG1 and IgG3, with 
a negative control.
IgG1+IgG3,
IgG1 in low titre (1:10)
IgG3 in high titre (1:100)
IgG1+IgG3
Low titre of IgG1 and high 
titre IgG3
IgG1/ IgG3 negative,
Ig G: Positive (Antibody screen 
positive)
Only IgG1 in high titre
Only IgG1 identified in high titre Both IgG1 and IgG3 negative in this positive 
antibody screen sample
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B. Reactions for Anti-IgG1/Anti-IgG3 subclasses 
 IgG1 IgG3 Control IgG 
 1:1 1:100 1:1 1:100  1:10 
Reaction 2+ - - - - 3+ 
Interpretation Moderate risk of hemolysis  (Subclass IgG1; low concentration) 
Reaction 3+ 2+ - - - 3+ 
Interpretation High risk of hemolysis ( Subclass IgG1; high concentration) 
Reaction 3+ 2+ 2+  - - 3+ 
Interpretation High risk of hemolysis ( IgG1 high concentration; low concentration IgG3) 
Reaction - - 3+ 2+ - 3+ 
Interpretation High risk of hemolysis  (Subclass IgG3; high concentration) 
Reaction - - 2+ - - 3+ 
Interpretation Moderate risk of hemolysis (Subclass IgG3; low concentration) 
Reaction 2+ - 3+ 2+ - 3+ 
Interpretation High risk of hemolysis (IgG1, low concentration, IgG3 in high 
concentration)  
Reaction 2+ - 2+ - - 3+ 
Interpretation Moderate risk of hemolysis (Subclasses IgG1 and IgG3, low concentration) 
Reaction 3+ 2+ 3+ 2+ - 3+ 
Interpretation High risk of hemolysis (Subclasses IgG1 and IgG3, high concentration) 
Note: The first two mircotubes contain  Anti-IgG1 (cell line M345/795) in two dilutions and 
third and fourth microtubes contains Anti-IgG3 (cell line M346/805) in two dilutions 
respectively.  
Reference: DAT IgG1/IgG3 ID-card, (Diamed GmbH 1785 Cressier FR Switzerland) BIO-RAD 
manual 
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STANDARD OPERATING PROCEDURES FOR ALL THE OTHER TESTS:  
B. ANTIBODY SCREENING:  
It is a test done routinely in our blood bank for all donor and patient samples to detect 
irregular antibodies. It is based on the IAT. This test uses patient’s plasma/serum against 
reagent red cells to detect unexpected antibodies. 
Screen cells used for this test are commercially prepared 2-5% suspension of group O cells 
obtained from individual donors and phenotyped for the most commonly encountered and 
clinically important red blood cell antigens, which is in contrast to the IAT which utilizes in-
house preparation of O-pooled cells from three phenotyped donors. Screen cells require the 
expression of the following antigens as per the BCSH guidelines for antibody screening in 
antenatal women: D, C, E, c, e, M, N, S, s, Lea, K, k, Jka, Jkb, Fya, Fyb.(2)  Group O red cells are 
preferred since it does not contain A and B antigens on the cell membrane, minimizing the 
chances of reacting anti-A and anti-B antibodies, and making it insensitive to the “regular or 
expected antibodies”.  
Both Rh Positive and Rh Negative cells are used in the screen cells. In the three cell vial 
which is commonly used in our blood bank, the Rh genotypes expressed are: (homozygous) 
R1R1, R2R2, R1R1. The homozygous expression of antigens for the major and clinically 
significant blood groups is crucial in choosing the appropriate screen cells to detect 
antibodies to antigens which even show dosage effect (eg. Kidd, MNS and Duffy). red cell.  
Material Required: 
1. Coombs cassette  
2. Biorad system centrifuge. 
3. Micropippette and tips 
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4. Low ionic strength solution (LISS) 
5. DiaCel – I-II-III Asia cells (Three cell panel reagent cells) 
6. Heat block (Incubator) 
Procedure: 
Antibody screening is done using commercial 3 cell panel DiaCel-I-II-III Asia 
Antibody screening is done using a Coombs cassette  
1. Label the coombs cassette with patient/donor ID 
2. And label three columns   S1, S2, S3 respectively 
3. Pipette 50 microlitres of reagent cells into columns labelled as S1,S2,S3 respectively 
4. And pipette 25 microlitres of patients / donor’s serum or plasma into all three wells. 
5. Incubate for 15minutes at 37 degrees. 
6. Centrifuge the card in Biorad centrifuge for 10 minutes at 900 rpm.  
7. Read the cassette from both sides 
8. Read and record the results. 
                      Gel card technique and range of reactions  
 
Fig 7: Interpretation of results using CAT 
 
Interpretation of column agglutination testing: 
 Negative  – All cells settle at the bottom. 
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 1+ Reaction - A button of cells at the bottom with most aggregates is remaining at  
the lower half of the beaded column 
 2+ Reaction - A small button of cells may also be visible at the bottom while  
aggregates observed throughout the length of the beaded column                   
 3+ Reaction - Most aggregates remains in the upper half of the beaded column. 
 4+ Reaction - Agglutinated cells form a band at the top of the beaded column. 
 +/- Reaction - Indeterminate. 
 Weak Reaction  - Granular suspension 
 MF Reaction   - Mixed field agglutination / double population. 
Reporting of results:  
Antibody screen – positive or negative –mentioning which screen cells are positive and 
strength of positivity. Entry of results to be made on the patient card filed in blood bank. 
Quality Control: 
To check the proficiency of screen cells and the coomb’s card, antibody screening is done 
with diluted anti-D IgG (1 in 10 dilution) as positive control and BLISS as negative control.  
C. ANTIBODY IDENTIFICATION 
Scope: This test enables identification of clinically significant antibodies and thus enables 
physicians to make clinical decisions regarding transfusions and antenatal interventions as 
appropriate  
Sample required:  Properly labelled 4ml EDTA samples /6ml clotted serum sample is 
required.  
 Material Required: 
1. Coombs cassette  
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2. Ortho Biovue system centrifuge 
3. Micropipette and tips 
4. Work rack/card holder 
5. LISS 
6. Heat block (Incubator)/ID Incubator 
7. 11 cell panel cells 
8. Patient cells – for auto control 
Procedure – Using 11 Cell panel cells from Ortho Clinical Diagnostics:  
1. Antibody identification is done on the Ortho Coombs cards in our blood bank 
2. Label the Coombs cards with patient hospital number and also mark the wells. 
3. Pipette 10 microlitres of  panel cells (from cell vials 1-11) into columns labeled 1-11 
and add patient cells (3% suspension) into well 12. 
4. Pipette 40 microlitres of patients / donor’s serum or plasma into all 12 wells followed 
by 40 microlitres of  BLISS 
5. Incubate at 37ºC for 10 minutes in the heat block  
6. Centrifuge the card for 5 minutes which will spin at 800 rpm for the first 2 minutes 
followed by 1500 rpm for the next 3 minutes (biphasic centrifugation) 
7. Read the cassette from both sides 
8. Grade and record the reactions  
9. Enter the reaction pattern onto the 11 cell panel worksheet 
 
Interpretation: 
1. The first well to be looked at prior to interpretation is well 12 – (the auto control) 
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2. If the auto control is positive – the test is usually un-interpretable unless it is 
extremely weak compared to the  positive reactions in other wells 
3. If the auto control is negative – then look at all the negative wells and cross out the 
antigens corresponding to the cells in that well 
4. Following this step look at the remaining antigens which are uncrossed out at the top 
row of the worksheet and see if the pattern of positivity fits into an antibody present 
against anyone / mixture of antigens 
5. If the auto control is positive, only wells with a higher grade of positivity should be 
identified as positive. Attempt to follow the process of interpretation as described 
above 
6. A standard approach has been to require that 3 antigen positive red cells react and that 
3 antigen negative cells fail to react for each specificity identified 
7. Correlate result by also doing a phenotype of the patient’s red cells – they should be 
negative for the antigen to which a corresponding alloantibody has been identified. 
Reporting of results:  Report should state that the antibody that was finally identified. 
 
 
D. COOMB’S TEST (DIRECT ANTIGLOBULIN TEST) 
Scope: To detect the presence of incomplete antibodies and compliment binding antibodies in 
serum/plasma or those coated on patients red cells  
Principle: Washed red cells which are coated with immune antibodies (commonly IgG) and 
complement components (generally C3) will show agglutination with broad spectrum AHG 
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reagent. The coating (sensitization) of red cells can occur in vivo or in vitro following 
incubation at 37deg C with serum containing antibody. 
Tests performed:  Direct Antiglobulin test (DAT) 
Methodology: 
Coombs test can be done by two different techniques  
A)  Tube technique 
B)  CAT 
Sample: Properly labeled 4ml EDTA samples /6ml clotted serum sample is required. 
Haemolysed samples are not acceptable.  
Material Required for Tube Method for DAT: 
Test tube 10X75 mm 
Test tube rack 
Marker 
Centrifuge / Serofuge 
Pasteur pipette 
Slide 
Normal saline 
Microscope 
Water bath at 37ºC 
Reagents for DAT:  
1. Coombs serum  
2. Negative control for DAT – 3-5% suspension of saline washed pooled O group 
cells    
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3. Positive control for DAT - Sensitized O pooled cells – (made by adding 0.5ml of 
IAT positive control to 1 ml of washed and packed O pooled cells and incubating 
at 37 deg for ½ an hour.  
Procedure for DAT: 
Tube technique: 
1. Take 3 tubes and label as patient ID, Positive control and Negative control 
respectively 
2. Add one drop of patient cells, positive control, negative control to the respective tubes 
3. Wash three times with normal saline 
4. After a final wash, decant the supernatant completely 
5. Add one drop of coombs serum to all the three tubes, mix and centrifuge at 3000rpm 
for 15 seconds 
6. Then dislodge the button gently and read both macroscopically and microscopically 
and grade the reactions as above. 
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GRADING OF THE REACTION FOR ALL TESTS DONE BY TUBE      
TECHNIQUE:  (Reference AABB Manual) 
            No agglutination   Negative 
Small aggregation   1+ Positive 
Medium size aggregates  2+ Positive 
Several large aggregates             3+ Positive 
One solid aggregate              4+ Positive 
The presence of haemolysis in the supernatant also  
indicates a positive reaction. 
Column Agglutination Technique:  
Materials Required:  Coombs card                                   Fig 8: Grading tube test reaction 
   ID Card Centrifuge 
   Normal saline 
   Micropipette and tips 
   Biovue system work rack/ID card holder 
    LISS 
    Heat block (Incubator)/ID card Incubator 
Procedure for DAT using Bio-Rad card 
1. Ensure that the cassette is at room temperature before use 
2. Label the cassette appropriately with patient ID, and control ID 
3. Add 50µl of 0.8% suspension of patient, positive and negative control cells 
respectively to all the 3 wells. 
4. Centrifuge the card in ID Card centrifuge for 10 minutes at 910rpm 
5. Read and record the reactions (read the card from both sides)  
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Grading of results by CAT as mentioned previously. 
Precautions: 
1. Adequate washing of sensitized cells is the critical part of the test. A trace amount of 
residual globulin, due to improper washing causes neutralization of the AHG Serum. 
2. A false negative reaction can occur if testing is interrupted or delayed. Washing of 
sensitized cells, addition of AHG serum and centrifugation must be quick and uninterrupted 
to avoid elution of antibodies attached to red cells and neutralization of AHG Serum. 
3. Inappropriate serum to cell ratio. 
4. Failure to add AHG reagent may give false negative results. 
5. Under centrifugation may not provide optimal conditions for agglutination. 
6. Failure to check the negative reaction microscopically. 
7. Over centrifugation packs red cells so tightly that they cannot be dispersed completely. 
8 Red cells may be agglutinated before washing and this may persist through the washing 
phase i.e. adsorption of complement during storage. In such cases a positive antiglobulin test 
may be incorrectly interpreted as a result of the IgG or complement coating. 
Documentation and Result entry: All reactions to be entered in the grouping worksheet All 
results to be entered with strength of reactivity on the patient grouping card. 
E. ANTIBODY TITRATION:  
Principle: Titration is a semi-quantitative technique of measuring the concentration of an 
antibody in a serum. The titre of an antibody is usually determined by testing the serial two 
fold dilution of the serum against selected red cells 
Specimen required: Properly labeled 4ml EDTA samples /6ml clotted serum sample is 
required. Haemolysed samples are not accepted 
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Materials: 
 1. 100µl automatic pipette and pipette tips 
2. Test Red blood cells: 3-5%  
3. Sterile 12X75ml test tubes 
4. Sterile saline 0.9% 
5. Serofuge 
6. Glass slides 
7. Water bath 
8. Microscope 
Procedure:  
1. Label the tubes according to the serial dilution usually 1:2 through1:1024  
2. Deliver one volume (100ul) of saline into all tubes 
3. Add one volume (100 µl) of the DTT treated serum/ plasma to tube 1:2  
4. Mix the contents of the tube several times and transfer one volume (100 µl) of the 
mixture from 1:2 to 1:4 and continue through the remaining tubes.  
5. Discard 100 µl  from  the tenth tube i.e. 1:1024 
6. Add one volume (100 µl) of 3-5% saline cell suspension of appropriate red cells to 
each tube 
7. Mix well and Incubate the serum cells mixture at 37deg C for one hour 
8. After one hour wash three times with normal saline  
9. Soon after the third wash decant the supernatant and add AHG serum 
10. Spin at 3000rpm for 15 seconds. 
11. Gently dislodge the button. Examine the test results macroscopically and grade and 
record the reaction. 
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12. If there is agglutination in the tube containing the most diluted serum, an end point 
has not been reached.  Prepare and test additional dilutions. 
       Grading of the Reaction: As for all test done by tube technique                     
Interpretation: The titre is the reciprocal of the highest serum dilution at which macroscopic 
agglutination is observed.  
Reactivity in the dilution control serum and no reactivity in the DTT treated indicate an IgM 
antibody 
Reactivity in the dilution control serum and in the DTT treated serum indicates an IgG and 
IgM mixture 
No reactivity in the dilution control serum indicates dilution of weak antibody reactivity and 
an invalid test 
Table 3: Antibody titration using DTT treated and not treated serum and interpreting 
results. 
 
Test Sample 1:2 1:4 1:8 1:16 1:32 Interpretation 
Serum+DTT 3+ 2+ 2+ 1+ 0 IgG 
Serum+PBS 3+ 2+ 2+ 1+ 0 
Serum+DTT 0 0 0 0 0 IgM 
Serum+PBS 3+ 2+ 2+ 1+ 0 
Serum+DTT 2+ 1+ 0 0 0 IgG+IgM 
Serum+PBS 3+ 2+ 2+ 1+ 0 
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Prozone Reaction: In a serum or plasma with a very high antibody concentration the 
prozone phenomenon may cause a weaker reaction in the lower dilutions than in the higher 
dilutions. 
Results: The titre of the antibody should be reported as follows: 
 Coombs titre performed with DTT treated serum –  
 Serum with PBS - 512    Serum with DTT  -128 
Results suggest a mixture of IgM and IgG antibodies. 
 BIAS:  
All efforts were be made to eliminate any bias in selection of patients. Despite this the 
prevalence of alloimmunization in antenatal women may show skewed results since CMC is 
a tertiary hospital and cases at risk are referred here. Instrument bias was likely to be 
negligible as variables were measured using calibrated and automated analyzers in the 
Clinical Pathology department and blood bank and all the serological tests done in the blood 
bank were run in duplicates. The column agglutination gel card, which was the novel test 
done in our study was interpreted by two individuals (principal investigator and an 
experienced technologist) independently. Investigator bias in interpretation of severity of 
HDFN was avoided as the investigator was not involved in the treatment directly. 
SAMPLE SIZE:  
Sample size was estimated to be approximately 84. 
Since severe HDFN due to IgG (IgG1 +IgG3) antibodies occurs in 30% pregnancies with Rh 
alloimmunization, according to a study conducted in KEM hospital, Mumbai.
1 
              Sample size = 4pq/d
2
                         (p=30%, q=70% and d= 10%) 
                                    = 4x30x70/ 10x10  = 84                                          
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Therefore if IgG1+G3= 28 and rest= 56, we expect 50% (P1) of the first group to be severe 
HDFN and 10% (P2) of the 56 may have severe disease.  To suggest IgG1+1gG3 is more 
significant than  
IgG1 alone:    Zα=1.96, Zβ= 0.84    
Sample size=  2pq ( Zα-Zβ)2/ (P1-P2)
2 
 
                                  =   2x30X70X8/ 40X40 
                                   =   21 
However in our study sample size achieved 68, since of the 85 women subtyped for IgG, 17 
were lost to follow up. 
 
Reference for calculation of sample size: Iyer YS, Kulkarni S.V.,Gupte S.C. KEM hospital, 
Mumbai; Distribution of IgG subtypes in maternal anti-D sera and their prognostic value in Rh 
haemolytic disease of newborn: Acta Hematologica 1992;88(2-3):78-81 
 
STATISTICAL ANALYSIS: 
 Mean, Standard deviation and 95% confidence interval (CI) was calculated for all 
continuous variables and Pearson and Fischer’s exact chi square was used for comparison 
of categorical data.  
Univariate and binary logistic regression analysis was used for comparing the categorical 
data and to calculate the odds ratio. P value <0.05 was considered significant.  
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RESULTS: 
A total of 3900 antenatal women had blood groups and antibody screens performed at CMCH 
between January 2013 and July 2014 and 85 of them who were antibody screen positive 
(2.17%) were included in the study. This was irrespective of their period of gestation.  
Demographics:  
Our cohort of patients included women mostly from Tamil Nadu (84%), and some from 
Andhra Pradesh (12%) and a few other states including Jharkhand, West Bengal and 
Karnataka  
Age:  
The mean age of the study population was 27 years (Max. 38, Min. 20years).   
Parity / Obstetric history: 
With regards to parity, 57 (74%) of these patients were multiparous, and 20 (26%primiparous 
(Fig 9). History on parity was not available for 8 women.   
 
 
 
 
 
 
 
 
 
 
Fig 9: Pie chart depicting the parity of the women found to be antibody screen positive  
Previous bad obstetric history/sensitizing event:  
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A bad obstetric history such as previous 1
st
 or 2
nd
 trimester loss, still births or intrauterine 
deaths or other fetal anomalies was recorded for 36 (63%) women among the multiparous 
group as shown in Fig 10. 
It was noted that among the multiparous group of women, those with gravid of 4 and more, 
all had a BOH (100%). However it is important to note that these numbers are small. In 
women who are G2 / G3 bad obstetric history was noted in 36% and 56% of women 
respectively. 
A transfusion history was documented for only two patients of our entire study cohort.                   
 
 
 
 
Fig 10: Depicting the BOH among women of different parity groups  
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Immuno-haematology parameters:  
  All blood groups were performed on two different platforms which included the microtitre 
plate and the column agglutination technique. For definition of D positivity D VI negative 
cards and D VI positive cards were both used on all samples in order to define any DVI 
positive individuals. However, in our study population no D VI positive individuals were 
identified. 
Antibody screen: 85 women were included in the study having a positive antibody screen on 
the commercial three cell panel from ID- DiaCell I-II-III Asia, DiaMed.  
The three cell panel included the following phenotypes - and a Mia phenotype as well: 
 R1R1 (CCD.ee) 
 R2R2 (ccD.EE) 
 R1R1 (CCD.ee) 
Antibody identification: Antibodies were further identified using the eleven cell panel from 
Ortho Clinical Diagnostics. 76 of these women were Rh negative. 73 of these 76 (85.8%) 
women had an anti D identified. 3 of 76 (3.53%) had more than one antibody identified 
namely anti-D and C. 
The remaining 9 antibodies were identified in Rh positive women. The antibodies identified 
included Anti-M in 3 (3.53%), Anti-E in 1 (1.17%), Anti-S in 1(1.17%), Anti-c in 1 (1.17%)  
and  Anti-Lea in 2 (2.35%) 
The antibody specificity could not be identified with the panel on hand in one patient. The 
diagrammatic representation of antibodies identified is shown in the figure below (Fig 11). 
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Fig 11: Pie chart showing the profile of antibody specificities in our study population 
Antibody titration: 
This test was performed when requested by the clinician and was available for 58 
alloimmunized women who were part of our study. 31 women (53%) had titres of less than or 
equal to 64, followed by 15 (26%) with titres between 128 and 256, while the rest 12 (21%) 
had titres of greater or equal to 512. 
 
Fig 12: Representing spread of antibody titre levels in the antenatal women 
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IgG subclasses identified (IgG1 and IgG3): 
This was performed using a DAT IgG1/IgG3 ID-Card from DiaMed GmbH, using the CAT. 
This test contains dilutions of IgG1 and IgG3 in 1:1 and 1:100 strengths alongside a positive 
and negative control.  The strength of each of the subclass IgG1 and IgG3 could therefore be 
interpreted according to positivity recorded on the relevant microtubes representing strengths 
of either 1:1 (low titre) or 1:100 (high titre). 
Our study showed the overall prevalence for IgG1 and /or  IgG3 subclasses in our population 
of alloimmunized antenatal women to be 48.23%.  
 
             Table 4: IgG1 and IgG3 results in women with a positive antibody screen 
 
 
 
 
 
 
Analysing it within subclasses showed the prevalence of IgG1/IgG3 as follows:  
 IgG1 only:  20%  
 IgG3 only:  4% 
 IgG1 + IgG3:  25% 
 Negative for both IgG1 and IgG3 - 51% 
** 32 women had high titres (in 1:100 dilution) for either one or both the IgG subclasses. 
IgG1/IgG3 result of patients with antibody screen positivity     
(n= 85) 
IgG1/IgG3 Positive IgG1/IgG3 Negative 
41 (48.23%) 44 (51.76%) 
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The positivity was contributed predominantly by a mixture of IgG1 and IgG3 (51%followed 
by IgG1 alone (42%), as shown in the diagram below. 
 
 
 
 
Fig 13: Representation of IgG1/IgG3 subclasses in our population 
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IgG1 and IgG3 titre levels:  
Our results show, that 44% of our study group did not have either IgG1 or IgG3, while for 
12% both these subclasses co-existed in high titres. It was interesting to note, that all three 
patients with IgG3, had the antibodies in low titres. (Table 5) 
 
 
Table 5: Titre of IgG1 and IgG3 antibodies in patients (n=85) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IgG1 IgG3 
Absent 
 
Low titre (1:1) High titre 
(1:100) 
Absent 44 (51.8%) 3 (3.5%) 0 
Low titre (1:1) 5 (5.9%) 1(1.2%) 5 (5.9%) 
High titre 
(1:100) 
12 (14.1%) 4 (4.7%) 11 (12.9%) 
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Antibody specificity and IgG subtypes: 
We performed IgG1 and IgG3 subclass testing on all antibody screen positive women and 
tabulated it against the antibody specificity identified.(Table 6)  
We noted that for women with only anti-D, 16% had IgG1 and 29% had both IgG1+IgG3.  
51% had neither. However in the three women with anti-D and C, all had only IgG1 
identified. In the patients with anti-M, 2 (67%) had IgG1. The remaining numbers are too 
small to derive any conclusions from. . 
 
Table 6: IgG subclass for all antibody specificities 
 
 
Antibody IgG1 IgG3 IgG1+IgG3 None Total 
D 12 (16.4%) 3 (4.10%) 21 (28.77%) 37 (50.68%) 73 
D&C 3 (100%) 0 0 0 3 
M 2 (66.67%) 0 0 1 (33.33%) 3 
E 0 0 0 1 (100%) 1 
S 0 0 0 1 (100%) 1 
C 0 0 0 1 (100%) 1 
Lea 0 0 0 2 (100%) 2 
Unidentified 0 0 0 1 (100%) 1 
Total women with antibody screen positive= 85 
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Follow up of Pregnancy and Diagnosis of HDFN: 
65 babies were live births in our study group, while loss of pregnancy was seen in 6 
pregnancies. There was an additional baby with clinically diagnosed hydrops with severe 
fetal anemia prescribed for intrauterine transfusion (which was not done) at 25 weeks of 
gestation, and further lost to follow up. This case has been included in further analysis as 
“severe” HDFN, even though the outcome could not be documented. In this case the mother 
had anti D, and had both IgG1 and IgG3 in high titres. The antibody titre level for this mother 
was 512. 
 Among the loss of pregnancies 2 were intrauterine deaths (in the first case, the fetus was Rh 
negative and the second was a primiparous woman with fetal movement not perceived at 22 
weeks of gestation), 2 were missed abortions, and 1 was a termination of pregnancy due to 
severe –pre-eclampsia. Another baby was a still birth among the twin pregnancies, but there 
was no clinical evidence of hydrops. These six cases were excluded due to causality being 
excluded or unestablished.   
Among the four twin pregnancies, two women delivered babies with a negative DAT. For 
one woman, both babies had a positive DAT. In the last case, one baby was DAT positive and 
the second was a still birth (as mentioned above). Each baby has been dealt with separately in 
the analysis. 
Additionally, nine Rh negative women with only Anti-D antibody identified, delivered Rh 
negative babies. They were excluded from correlation with severity of HDFN. 
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*17 pregnancies were lost to follow up. 
 
Fig 14: Flowchart to illustrate patient follow up and results 
      
 
Antenatal women with positive 
antibody screen (N=85) *
Total antenatal women for whom blood grouping and 
typing done in CMC over study period (N=3900)
Babies followed up including 4 twins (N=72)
Live births (N=65) 1- Hydrops
Excluded-Abortions/IUD (N=6)
Remaining  (N=56) Excluded- Rh negative (N=9)
DAT positive (N=37) DAT negative (N=19)
Study group
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             Data about the newborns: 
              Among the 65 babies followed up in the study, we observed that approximately 40% 
required a caesarean section while the rest had a normal or assisted delivery. 46% of the 
births were prior to 37 weeks and the rest were term or post term deliveries. In our newborn 
population 58% newborns were of normal weight (>2.5kg), 37% were less than 2.5kg (Low 
birth weight), 2% with very low birth weight (between 1.5 and 1kg) and 3% were extremely 
low birth weight (less than 1kg). 
  Of the 37 DAT positive live births, 10 required no treatment and were only followed up 
with haemoglobin and bilirubin levels, while the remaining 27 required either an IUT, 
phototherapy, exchange transfusion or multiple treatment modalities. It was noted that 3% 
(1/37) required an intrauterine transfusion and 14% (5/37) needed an exchange transfusion, 
and one required a top up transfusion 
 
.Table 7: The baseline features and treatment requirement of the live births in the study 
population 
 
 
Variables Groups n(%) 
Delivery (Live 
births) 
Normal 38(58.46) 
LSCS 27(41.53) 
Term  Pre term 30(46.15) 
Term 35(53.84) 
Weight ELBW 2(3.07) 
VLBW 1(1.53) 
LBW 24(36.92) 
Normal 38(58.46) 
Sex (Live 
births) 
Male 36(55.38) 
Female 29(44.61) 
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HDFN in Newborn:  
The newborn was evaluated for presence or absence of HDFN. If present, severity was 
assessed. Classification of hemolysis and severity of disease was done in consultation with 
the department of Neonatology into one of three grades - namely Mild/ Moderate/ Severe 
HDFN. This was based on therapeutic interventions as per guidelines laid down by the 
Department of Neonatology for this study, since modalities of therapy are decided based on 
severity of disease 
 
Table 8: Categorization of disease severity on the basis of treatment modality required 
in DAT positive live newborns 
 
 
Categorization of disease severity on the basis of treatment requirement 
 (DAT positive; n= 37) 
Mild disease Moderate Severe* 
10 (27.00%) 20 (54.05%) 7 (18.91%)  
*Total patients with severe disease were 8, seven live births and one hydrops with outcome      
not known. 
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Correlating IgG1 IgG3 subclass typing results with presence / 
severity of HDFN 
 
           Women with IgG1 only:   
            There were 17 women who had IgG1 only, 5 with low titre and 12 with high titre. Of these, 5 
with high titre were lost to follow up (all with high titre of IgG1). 
            Follow up was therefore available for 12 women (2 who delivered twins, one of which was a 
still birth).Of these 5 were low titre and 7 were high titre IgG1. 
            Among the 5 patients with low titre IgG1, one baby was Rh negative born to an Rh negative 
mother with anti D and was thus not included for follow up. The remaining 4 babies born to 
mothers with low titre IgG1 developed moderate disease, requiring phototherapy. Among the 
7 mothers (8 babies, including the twin) with high titre of IgG1, one baby had mild disease, 
five babies had moderate HDFN, while two had severe HDFN category.  
            The two newborns with severe disease were born to mothers with Anti-D, with antibody titres 
of 128 and 512 respectively. 
 
 
 
Fig 15: To illustrate the outcome of pregnancy in women with only IgG1 antibodies (5 
with high titre IgG1 were lost to follow up). Both severe HDFN cases had high titres of 
IgG1. 
1, 8% 
1, 8% 
9, 69% 
2, 15% 
Rh negative 
Mild disease 
Moderate disease 
Severe disease 
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Women with only IgG3:  
Three patients were identified to have only an IgG3 antibody in our study population and 
interestingly all three of these patients had the antibody in low titres (1:1). One of them was 
lost to follow up. The two newborns in the category of IgG3 alone in maternal serum, 
suffered from mild and moderate form of disease respectively. 
         
Women with both IgG1+IgG3:  
Among the 21 women with IgG1+ IgG3, 12 of the 21 (57%) had high titres of both IgG1 and 
IgG3, and hence showed positive results in the 1:100 dilution microtubes of both IgG1 and 
IgG3. There were four patients each in the category with high IgG1 and low strength IgG3 
and vice-versa. There was only one patient who had low levels of both the subclasses.    
  
Table 9: Distribution of IgG1 and IgG3 titres in patients with a combination of these 
subclasses 
 
In patients with IgG1 + IgG3 (n=21) 
IgG1 H + IgG3 H 
IgG1 1:100 
IgG3 1:100 
IgG1 H + IgG3 L 
IgG1 1:100 
IgG3 1:1 
IgG1 L + IgG3 H 
IgG1 1:1 
IgG3 1:100 
IgG1 L + 1gG3 L 
IgG1 1:1 
IgG3 1:1 
11 (52.38%) 4 (19.04%) 5 (23.81%) 1 (4.76%) 
       H-High titre (1:100), L- Low titre (1:1) 
 
Of the 21 patients with both IgG1 and IgG3 identified, 4 were lost to follow up (1- IgG1H 
+IgG3H, 1- Ig1 H+IgG3L, 2- IgG1 L+ IgG3 H). 
Of the ten patients with high titres of both IgG1 and IgG3 who delivered in CMCH, five had 
newborns with moderate HDFN, and five had the disease in the severe form. 
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Of the three patients with high titre of IgG1 and low titre of IgG3, one newborn was DAT 
negative; the other two had had mild and moderate disease respectively. 
Of the three with IgG3 in high titre and IgG1 in low titre, two had babies with moderate 
HDFN and one was severe. 
The one mother with both the antibodies in low titres, gave birth to a baby with moderate 
HDFN 
Overall more than 90% of babies born to mothers with a combination of IgG1 and IgG3 
developed moderate to severe disease irrespective of the titre of antibody.  
 
 
 
 
Fig 16: Pie chart to illustrate outcome of pregnancies in women with IgG1+IgG3 (of 17- 
five were lost to follow up). 
 
 
 
 
 
1, 6% 
1, 6% 
9, 53% 
6, 35% 
DAT negative 
Mild  
Moderate 
Severe 
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Negative for both IgG1/IgG3:  
There were 44 mothers negative for IgG1 or IgG3. Among them 7 were lost to follow up. Of 
the remaining 37, two mothers had twin deliveries. There were also 5 IUD/abortions in this 
group which were excluded for other causes. Of the 34 babies present, 8 were Rh negative 
babies born to mothers with Anti-D. Of the remaining 26, 18 were DAT negative and 8 were 
positive. Of these 8 were babies, 7 were categorized as mild disease (88%), except one who 
was labelled as moderate HDFN (12%).  
 
 
 
 
 
 
 
 
Fig 17: Pie chart to illustrate the severity of disease in babies born to mothers, negative 
for IgG1 or IgG3 
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Fig 18: Severity of HDFN in comparison to IgG1/G3 subclass in mother (baby with    
clinical hydrops included) 
 
Of the total eight severe cases of HDFN seen in our study (including the baby with clinically 
diagnosed hydrops), we noted that two were born to mothers with high titres of IgG1 alone 
while the rest were born to mothers having both IgG1+IgG3. 
 
 
Fig 19: Pie chart to show the patients of Severe HDFN and the IgG subclass in the   
maternal serum 
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Analysis: 
Correlating disease severity with the presence or absence of IgG1/ G3 subtypes 
The Pearson’s Chi square test was applied to assess significance of the impact of IgG1 
subtype positivity on HDFN severity.  
The table below compares severity of HDFN in babies born to mothers with 
1. No IgG1 or IgG3 
2. IgG1 or IgG3 
3. Both IgG1 and IgG3 
We observed a highly significant difference (p<0.001) in severity of disease when comparing 
mothers negative for IgG1 and G3 as against mothers with one subtype IgG1/ IgG3 and a 
combination of IgG1+IgG3 which was progressive with P values which were significant 
between each subgroup (p<0.001).  
 
Table 10: Comparing the IgG subclass and disease severity in all newborns 
 
IgG type Disease outcome  Total 
 No/Mild Moderate/Severe  
None 25 1 26 
 86.20% 3.57% 45.61% 
IgG1/IgG3 2 12 14 
 6.89% 42.86% 24.56% 
IgG1+IgG3 2 15* 17 
 6.89% 53.57% 29.82% 
Total 29 28 57 
 100.00% 100.00% 100.00% 
    
                 p value <0.001  
*Baby with hydrops with documented clinically diagnosed hydrops was included in 
the analysis under severe disease category, with mother having IgG1+IgG3  
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This difference was still significant when comparing only DAT positive cases (p<0.001). 
 
         Table 11: Comparing severity of HDFN with respect to IgG subclass in live newborns 
with DAT positive result. 
 
IgG type Disease outcome Total 
 Mild Moderate/Severe  
None 7 1 8 
 70.00% 3.70% 21.62% 
IgG1/IgG3 2 12 13 
 20.00% 44.44% 35.13% 
IgG1+IgG3 1 14 15 
 10.00% 51.85% 40.54% 
Total 10 27 37 
 100.00% 100.00% 100.00% 
    
 P< 0.001  
 
*”None” - patients with IAT positive but not having IgG1 or IgG3, 
 
 
For eight of our maternal samples, the negative control showed a positive reaction while 
performing the test. These samples were further treated with DTT (0.01N) in equal volume 
for 30 minutes at 37 degrees, and the test repeated. The negative control was negative after 
DTT treatment and the test interpretable. This highlighted an underlying IgM component of 
Anti-D along with the IgG. Subsequently to confirm the same,  titre levels were done on both 
DTT treated and untreated serum, in a normal saline and Coomb’s card. There was a 
difference between the  saline titre and coombs titre – albeit small – being a one titre level 
difference , indicating a low titre of the IgM, Anti-D alongside the IgG component. 
 
We compared the severity of disease with the IgG subclass in the mother, and we noted that 
75% (9/12) of mothers with IgG1 had babies with moderate disease and an additional 17% 
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(2/12) had severe disease. In the case of IgG1+IgG3, 50% babies had moderate disease, and 
44% had the disease in severe form. Overall the Pearson’s chi square did not show a 
significant difference between the impact of IgG1 alone as compared to a combination of 
IgG1 and IgG3. However, logistic regression analysis shows the odds of developing severe 
HDFN to increase 18 fold when IgG1 and IgG3 are present in combination. 
 
Antibody titre levels in different groups of IgG subclasses: 
Below is the diagrammatic representation of the antibody titre levels in comparison to the 
IgG subclass which was identified. 
Of the 23 women with no IgG1 or IgG3, 21 (91%) had the titre levels of less than or equal to 
64, while the remaining 2 (9%) had levels between 128 and 256. 
In the group of patients with both IgG1 and IgG3, 8 (38%) had titre levels between 128 and 
256, followed by titres of greater than 512 in 7 (33.33%) and less than or equal to 64 in 6 
(28.6%) patients.  
 
Table 12: Distribution of the antibody titre levels in the antibody screen positive women 
Titre Not 
IgG1/G3 
IgG1 alone IgG3 alone IgG1+IgG3 Total 
<64 21 3 1 6 31 
128-256 2 5 0 8 15 
>512 0 4 1 7 12 
Total 23 12 2 21 58 
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To understand if the IgG1 and IgG3 class contributed to HDFN independent of the overall 
titre levels, we compared disease severity among those with no IgG1 or IgG3 to those with 
one or both of these, in the group of patients with overall low to intermediate titre levels( <64 
and 128-256). An extremely significant difference was noted (p<0.001), which helped infer 
that even in low titres IgG1/ IgG3 identified could cause more severe disease than in those in 
which it was absent. In low/intermediate titre levels, we noticed that only one patient with 
neither IgG1/IgG3 had a baby with moderate disease, however in those with either IgG1 
and/or IgG3 despite having low to intermediate titre levels, 16 babies developed moderate to 
severe HDFN. 
 
 
Table 13: Comparing disease severity in patients with neither IgG1/IgG3 to those with 
one or both of these subclasses, in patients with a low or intermediate antibody titre 
level 
 
 
IgG subclass Disease severity (low/intermediate titre) p value 
Moderate/Severe No/Mild disease 
Negative for IgG1 
and /or IgG3 
1 12 p<0.001 
IgG1 and/ or IgG3 
present 
16 2 
*Rh negative babies not at risk were excluded from this analysis 
 
 
We noted that antibody titre levels also correlated significantly with severity of disease 
(p<0.05). This analysis included all newborns including those with a final DAT negative 
result. The difference was more significant between <64 titre and the rest because of greater 
percentage of patients in this group. 
 
 
 
96 
 
 
Table 14: Comparing the antibody titre levels in maternal serum to the severity of 
disease in newborns in all patients with titres documented during antenatal visit. 
 
 
Titre Disease outcome Total 
 No/Mild Moderate/Severe  
<64 12 09 21 
 75% 37.50%         51.21% 
128-256 3 7 10 
 18.75% 29.17% 24.39% 
>512 1 8 09 
 6.25% 33.33% 21.95% 
Total 16 24 41 
 100.00% 100.00% 100.00% 
    
                      p = 0.006  
*Rh negative babies born to mothers with Anti-D were excluded 
 
In view of the significant difference in disease severity among babies born to mothers with no 
IgG1/ IgG3 identified compared to those with IgG1/IgG3, and also a noticeable difference in 
titre levels of these two groups, we further compared the titre levels of patients with either 
IgG1 or IgG3 and those with a combination of the two antibody subclasses. 
 
Due to the small numbers available the Fischer’s exact test was used for comparison between 
titre levels and IgG subclass. There was no significant difference noted in the antibody titre 
levels of women with only antibody screen positivity and no identifiable IgG1/IgG3, and 
group of women who had one or both the IgG antibodies (p>0.05). Only patients who gave 
birth to DAT positive newborns were included for this analysis. 
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Table 15: Comparison of titres in mothers who were IgG1 / IgG3 positive vs those who 
were negative who both delivered DAT positive babies 
 
 
 
Titre IgG subclass Total 
 None IgG1/IgG3/both  
<64 5 10 15 
 83.33% 40.00% 48.39% 
128-256 1 7 8 
 16.67% 28.00% 25.81% 
>512 0 8 8 
 0.00% 32.00% 25.81% 
Total 6 25 31 
 100.00% 100.00% 100.00% 
    
 p= 0.192  
 
 
When we compared the available antibody titre levels between IgG1 or IgG3 (12) patients 
and those with IgG1+IgG3 (21) we did not find it to be significant (p>0.05).  
 
Table 16: Comparing the antibody titre levels of patients with IgG1 or IgG3 and 
IgG1+IgG3 
 
IAT titres IgG subclass Total 
 IgG1/IgG3 IgG 1+ IgG3   
<64 4 6 10 
 33.33% 28.57%     30.30% 
128-256 4 8 12 
 33.33% 38.09% 36.36% 
>512 4 7 11 
 33.33% 33.33% 36.67% 
Total 12 21 33 
 100.00% 100.00% 100.00% 
  p =  0.934  
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Further univariate logistic regression analysis was done to compare the disease severity and 
the IgG sublclass. Our results show that the risk of newborn developing severe HDFN 
increases 18 times when IgG1 or IgG3 is present as compared to none of these (only antibody 
screen positive). When IgG1+IgG3 is present there is an additional 18 times more risk of 
severe disease as compared to either of them alone. Thus IgG1+IgG3 served as indicators for 
more severe form of HDFN as compared to each of them alone.  
Our results highlighted the significance of identifying IgG subclass as an independent 
prognostic marker for HDFN.  
 
Table 17: Univariate logistic regression analysis, showing the odds- of HDFN when 
IgG1/IgG3 or IgG1+ IgG3 is present in the mother. Compares the HDFN in all live 
newborns  
 
 
 
Logistic regression analysis (Univariate)   
    
Outcome 
Odds 
ratio P 
95% Confidence 
interval 
IgG1/IgG3/IgG1+IgG3 18.18 <0.001 4.70  - 70.29 
    
 
 
 
A univariate logistic regression analysis was also used to calculate the odd of HDFN when 
compared to the antibody titre levels to look upon it as an independent prognostic marker of 
HDFN. Our results showed that the risk of HDFN increased 7 times (odds ratio, with a CI of  
4.7-70.3)  when titre was 128-256 when compared to that of less than 64, and a further 7 
times when the titres were greater than 512 as compared to the range of 128-256. 
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Table 18: Univariate logistic regression analysis for titre of antibodies detected and 
odds of developing HDFN 
 
Logistic regression analysis (Univariate)   
     
 
Outcome 
Odds 
ratio P 
95% Confidence 
interval 
Titre 7.43 0.008 1.69 – 32.64 
    
 
 
Since IgG subtypes independently showed significant difference with severity of disease and 
so did the antibody titre levels with an odds ratio of approximately 7 and it tended towards 
significance. It helped realize that both played a vital role in predicting severity of HDFN and 
could not be looked upon in isolation. This lead to us to do a binary logistic regression 
analysis, to see the odds of developing severe HDFN, using IgG subclass, antibody titre 
levels and the IAT strength of reaction. 
 
 
Table 19: Binary logistic regression to compare severity of HDFN in relation to IgG 
subclass, antibody titre levels and IAT strength 
 
 
Binary logistic regression analysis  
    
Outcome 
Odds 
ratio P 
95% Confidence 
interval 
IgG1/IgG3/IgG1+IgG3 6.91 0.013 1.50 - 31.89  
Antibody Titre 2.30 0.437 0.281 – 18.83 
IAT  7.19 0.106 0.656 - 78.92 
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The overall odds of severe HDFN increased 7 times when IgG subclass, antibody titre levels 
and IAT strength were compared together, through binary logistic regression analysis. The 
odds of having severe disease was seven times more when IgG1/IgG3 was present in 
comparison to none of the antibodies, and a further seven times when IgG1+IgG3 was 
present in comparison to IgG1/IgG3 alone. 
 
DAT result compared to severity of disease: 
We compared the strength of the DAT result with the severity of disease in the newborns, In 
patients mild disease the DAT strength ranged from 1 to 2 only, while those with moderate 
disease had DAT ranging from 1 to 3+ and finally all patients with severe disease also had a 
corresponding strong DAT results (3+/4+). 
 
 
DAT was not available for baby with hydrops and outcome not known  
 
                     Fig 20: Severity of disease versus the DAT strength observed  
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The DAT strength in the Rh positive newborns was correlated with the disease severity. It 
was found to be highly significant (p<0.001) through Pearson chi square test, suggesting that 
a positive DAT in a high risk or clinically suspected HDFN is a strong indicator. 
 
 
 
Table 20: Association between DAT and outcome of disease in all newborns 
 
DAT outcome  Disease outcome Total 
Strength of reaction Mild Mod/Severe  
    
0 19 0 19 
 65.51% 0.00% 33.92% 
1 4 3 7 
 13.79% 11.11% 12.5% 
2 6 7 13 
 20.68% 25.92% 23.21% 
>3 0 17 17 
 0.00% 62.96% 30.36% 
Total 29 27 56 
 100.00% 100.00% 100.00% 
    
p < 0.001  
      
             Of the 26 births, in mothers found to be antibody screen positive but negative for 
IgG1/IgG3, 8(31%) had newborns who were  DAT positive In comparison, among the 30 
pregnancies with antibody screen positivity and positive results for IgG1/IgG3 subclass or 
both , 29(96.6%) newborns were DAT positive. 
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                              Table 21: IgG subclass and DAT results of newborns 
 
 
 
      
 
  The above table is self explanatory, in that the greatest impact comes from a combination of 
IgG1 and IgG3. However, in the group of mothers who were antibody screen positive, but 
IgG subclass negative on this card, we still identified 8 babies with DAT positivity. However, 
7of the8 babies (87.5 %) manifested as only mild HDFN, with one baby showed moderate 
disease. This is in contrast to the other 3 groups described in detail above. 
 
We compared the IgG subclass, titre levels, other haematological and biochemical parameters 
and treatment modality in the severe cases. Table below describes each of these seven cases. 
  
 
 
 
 
IgG subclass in 
maternal serum 
DAT positive DAT 
negative 
Total (n=56) 
IgG1 12 
(1-Mild, 9-Moderate, 2-
Severe) 
0 12 
IgG3 2 
(1-Mild,1-Moderate) 
0 2 
IgG1 + IgG3 15 
(1-Mild,8-Moderate, 6-
Severe) 
1 16 
Negative (Antibody 
screen positive) 
8 
 (7-Mild, 1-Moderate) 
18 26 
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Table 22: Profile of babies with severe HDFN in our study 
 
 
The table above depicts the profile of all severe live birth HDFN cases encountered in this 
study. The IgG subclass identified in the maternal serum, with the titre levels of antibodies in 
(). All these babies survived except 4
th
 newborn who developed bilirubin encephalopathy. 
ET- Exchange transfusion, IUT- Intrauterine transfusion, BT- blood transfusion 
 
 
 
 
Sn
o. 
IgG 
subclass 
(Titre) 
Gestation 
(weeks) 
Wt 
(gm) 
Hb 
(gm%) 
Retic 
(%) 
Bil 
(mg
/dl) 
Max 
Bil. 
ET/IUT/
BT 
Outcome/Remarks 
1 
 
IgG1+IgG3 
(1024) 
35 
 
2000 
 
7.6 
 
18.8 
 
10 
 
17.5 
 
ET 
 
Live 
 
2 IgG1+IgG3 
(512) 
38 
 
2500 
 
6.5 
 
22.5 
 
9.2 
 
 
 
ET 
 
Live 
 
3 
 
IgG1 (512) 33 
 
2020 
 
11.8- 
1
st
 unit 
5.9- 2
nd
 
unit 
16.8 
 
6.8 
 
17.8 
 
2 top up 
transfusio
n 
 
Live 
Cord Hb- 12.1, 
Cord bil-3.6, ET 
avoided since rate 
of rise <0.5gm/dl/hr 
 
4 
 
IgG1+IgG3 
(1024) 
38 
 
3400 
 
13.3 
 
- 
 
53.
6 
 
53.6 
 
ET 
 
*Outside delivered, 
Bil. 
encephalopathy, 
 
 
5 
 
IgG1+IgG3 
(128) 
32 
 
1960 
 
- 
 
- 
 
- 
 
8.1 
 
IUT thrice 
 
Ascites 
1
st
 IUT- 29 weeks , 
2
nd
 IUT (Hb 10.3), 
3
rd
 IUT (Hb 6)  
Live 
6 IgG1+IgG3 
(1024) 
38 2760 10.3 15.9 16.
0 
- ET Live, Pericardial 
effusion and ascites 
7 IgG1 (128) 39 3100 11.7 6.74 5.4 
to 
10.
4 
in 
6 
hrs 
- ET Live 
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DISCUSSION:  
 
Red cell alloimmunization in the antenatal population has been a challenge for many decades.  
However with better anti D prophylaxis programmes, greater awareness of the problem, and 
better tools to diagnose the same, this has been declining. However, there has been constant 
work to develop tests which would predict the onset of HDFN, and also assess severity, in 
order to put therapeutic interventions in place on time.  
It is against this background that we initiated this study. The IgG subtypes have been studied 
by many groups worldwide as they tend to impact on the presence/ severity of HDFN. Many 
groups have used various methods to qualitatively and quantitatively determine the 
subclasses. There is western literature which has looked at the significance of subclasses and 
the clinical outcome of pregnancy, but only one major study from India by Iyer et al. (1992) 
which explored the prognostic value of the IgG subclasses.(3,4) (74).  
 
Our study was done in a tertiary hospital in South India. The prevalence of alloimmunization 
was found to be 2.17%, this is slightly higher than the prevalence of  1.48% reported in our 
previous study and also as compared to 1.25% prevalence reported by Pahuja et al. from 
Delhi, North India.(19,20)The reasons for this could be multi-factorial.  It could be attributed 
to greater awareness as antibody screening has become routine protocol in many centres, and 
hence greater pickup of antibodies, and referrals to our institution as a tertiary care centre, 
being a reason. It could also be due to the fact that antibody screening with the standard three 
cell panel has become more extensively used. All previous literature have, reported a varying 
range of prevalence of alloimmunization, which differs in different geographical areas and 
populations. It has been found to be as high as 2.71% reported by De Vrijer et al. 
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(Netherlands) to as low as 0.4% as reported by Gottvall et al. from Sweden. Among Asian 
countries Lee et al. (2003) from China have reported a prevalence of 0.79%.(19) (98) 
The most common alloantibody in our antenatal population was identified to be Anti-D. Of 
the 85 women found to be antibody screen positive during an antenatal visit, 85% had Anti-
D, this is similar to the study by Pahuja et al. who found anti-D alone to contribute 78.43% of 
all alloimmunization(19). However Al-Ibrahim et al from Saudi Arabia found Anti-D to 
contribute only 52.38% to the alloimmunization of antenatal women and similarly Dajak et 
al. from Croatia reported Anti-D in 55% alloimmunized women.(27)(99) This was a contrast 
from results from the Indian subcontinent. In a report from America in 2000, it was reported 
that almost 6.8 per 1000 live births in America were affected by Rh sensitization.(68) 
 It was interesting to note the presence of other clinically significant antibodies, such as Anti-
C, Anti-M, Anti-E, Anti-S and Anti-c in our antenatal alloimmunized population. Anti C and 
Anti-M made up 3.5% of the cases each respectively. There were only three patients in our 
study group with multiple antibodies identified, and all of them had a combination of Anti-D 
and C. Our profile of alloantibodies was very similar to that of Pahuja et al. , Anti-D in their 
study was followed by anti-C, and among the other significant blood group systems was the 
MNS with Anti-M having a frequency of 3.5%.(19) According to our previous study from 
CMC by Varghese et al. Anti-D contributed 34.2% of the alloimmmunized women, followed 
by Anti-Lea and Anti-Leb, which made up 10% and 8% respectively. Among the clinically 
significant alloantibodies, were those with a combination of anti-D and C (4%) or Anti-E and 
Anti-K (1.3%), the other antibodies reported were, Anti-c, Anti-C, Anti-M and Anti-Jka and 
Jkb, there were almost 37% cases in which antibodies could not be identified.(20) However 
now with antibody screening having become a routine, standardized practice followed by 
identification, we had only one case in which the antibody could not be identified using the 
11 cell panel available. 
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We found that among our primiparous population of antenatal women, five had babies with 
HDFN. The severity of disease ranged from mild (2/5) to moderate (3/5). In contrast to long 
standing understanding of Rh related HDFN, which states that the first pregnancy is not 
affected, it has been reported in literature to occur in primiparous women with no history of 
transfusion or any known sensitizing event.(27)(100) 
 There was a bad obstetric history for almost 63% of our study group, which seemed more 
likely to have caused the sensitizing event, for the subsequent pregnancies, this was similar to 
the observation of Koelewijin et al. (Netherlands) who reported it to be approximately 
54.28% in the alloimmunized antenatal women.(101). Pahuja et al. from Delhi have also 
reported a bad obstetric history in 62% of their alloimmnuzed antenatal women, which is 
very similar to ours.(19) In a study by Koelewijin et al. looking at profile of antenatal women 
at risk of HDFN, they observed that the Rh sensitization in antenatal women was most likely 
to be due to inadequate dose of Anti-D immunoglobulin, since most guidelines suggest a 
Kleihauer Betke test for calculating the dosage, which itself does not have sufficient 
sensitivity and specificity. They have attributed the inadequacy of the test in various studies 
to factors such as, different cut-offs in different laboratories, that the small amount of FMH 
capable of causing sensitization could be missed by the manual form of the test and lastly-
that for evidence based guidelines larger number of cases need to be studied.(87)  
 
IgG subclasses: We found the overall prevalence of IgG1 to be 20%, IgG3 4% and 25% for 
IgG1+IgG3 together in our population of antenatal women. The remaining almost 50% were 
antibody screen positive but did not have either IgG1 or IgG3. There are studies done in the 
Caucasian population, which have reported that the predominant category of antibodies in 
patients alloimmnunized with anti-D are IgG1 and IgG3, and rarely IgG2 and IgG4.(3,4,75) 
A study by Lubenko et al. has further gone on to report that IgG2 and IgG4 tend to decrease 
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in pregnancies at risk of HDFN as compared to those not at risk. (102) It was interesting to 
compare our results to those published by Pollock et al. in their study from Canada. They 
found that of 98 women identified to have Anti-D, 32 (33%) had IgG1, 3 (3%) had IgG3 and 
63 (64%) had both IgG1+IgG3.  
According to their results, in patients with combination of both IgG1+IgG3, IgG1 was the 
predominant subclass. They did not report on any women with IgG2 and IgG4.  In our study 
it was IgG1 and IgG3 which were looked at to prognosticate HDFN in view of all previous 
literature, which state that these are the predominant subclasses involved in causation of 
HDFN. In contrast, IgG2 the least efficient among all the IgG subclasses in crossing the 
placenta, and also the contribution of IgG2 and IgG4 in HDFN is limited due to absence of 
receptors for these on the monocytes.(74) 
We identified IgG1 alone in 17 of our 85 (20%) antenatal women including all antibody 
specificities. It was in 12 of 73 (16%) in those with Anti-D alone. This is however lower than 
that reported by Iyer et al. from Mumbai who studied only Anti-D alloimmunized women, 
and found IgG1 to be the major subclass identified in their study population which was in 52 
of 107 women (48.6%).(74) Among western studies, Pollock et al. have reported isolated 
IgG1 in 32.6% cases.(4) Overall the prevalence of IgG1 alone appears much less compared to 
other published literature. 
IgG3 alone was found in only three of our 85 study patients (3.5%). Among two women who 
were followed up, they had babies with mild and moderate disease respectively. Previously 
Iyer et al. and Pollock et al have reported the prevalence of IgG3 in their studies to be 12% 
and 3% respectively. In both studies they found that when IgG3 was present alone these 
women also had low antibody titres. In the study by Pollock et al. all of them had titres not 
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more than 4.(4,74) In our patients two had documented titre levels of 16 and 512 respectively. 
The patient with titre of 512 was eventually lost to follow up. 
 Our study population had majority with IgG1+IgG3 (25%) in all antibody specificities 
together and it was 29% (21 of 73) in those with Anti-D alone. This was higher as compared 
to Iyer et al. who reported IgG1 and IgG3 together to be in 23 of 107 cases (21.4%).(74) 
Pollock et al. found IgG1 and IgG3 in combination to be present in the highest proportion of 
patients, 64.2%. In our study also IgG1 and IgG3 together contributed the majority of patients 
who had either IgG1 or IgG3 present. 
The majority of our antenatal alloimmunized women, 44 of 85 patients (52%) were antibody 
screen positive, but negative for both IgG1 and/or IgG3. Iyer et al reported this group as 19 of 
107 patients (18%), but interestingly Pollock et al have no patients from their study group of 
98 who had neither IgG1 and/or IgG3.(4,74) 
Our study looked at IgG1 and IgG3 subclassses in all antibody specificities that were 
encountered. However due to very small numbers in patients alloimmunized with antibodies 
other than Anti-D it was difficult to draw any inference. Most studies have looked at IgG 
sublclasses in Rh (Anti-D) sensitization alone. We found that in patients with both Anti-D 
and C, all 3 cases (100%) had IgG1 alone, while 2 of 3 (67%) cases with Anti-M alone had 
only IgG1 and one case had neither IgG1 and/or IgG3. All other antibody specificities were 
negative for both these subclasses of IgG. There is one study by Thomas et al (1995), which 
carried out a quantitative assay of IgG subclasses in alloantibodies other than Anti-D. In their 
profile of antibodies studied which included Anti-S, -E, -Jka, and –Fya, IgG1 or IgG3 
accounted for greater than 50% of the antibody subclass in babies which finally developed 
HDFN.(77)     
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We followed up 68 pregnancies to correlate the IgG subclass identified with the outcome of 
pregnancies. 56 newborns were Rh positive (and of these 37 newborns were DAT positive 
and 19 DAT negative). Of the live births, there were overall, 10 babies with mild disease, 20 
with moderate and 7 with severe HDFN. There was also an additional case of severe HDFN 
who was planned for an IUT, but was subsequently lost to follow up and therefore whose 
outcome was not known.  
It was observed that in patients with severe HDFN babies were born to mothers mostly with 
high titres of both IgG1 and IgG3, 75% (6/8), while two were born to mothers with high titres 
of IgG1 alone (25%). Iyer et al reported severe disease in 68% of the newborns followed up 
and the majority were born to mothers with IgG1 alone (53%), as compared to those with 
IgG1 and IgG3 together (25%). This was found to be in contrast to our findings.(74) 
However Pollock et al. have reported severe HDFN to be more frequently encountered in 
mothers with IgG1 and IgG3 together (67%) as compared to those with IgG1 alone (32%).(4) 
Of the five primiparous women who had babies with HDFN, it was noted that three had IgG1 
alone, while two were negative for IgG1 and/or IgG3.   
 We used logistic regression analysis to calculate the odds of severe HDFN in respect to the 
IgG subclass in maternal serum. We observed that the odds of developing severe HDFN were 
eighteen times higher (p<0.005, CI 4.7-70.3) in patients with no IgG1/IgG3, to those with one 
of the latter and the odds further increased 18 times when the two were present in a 
combination. Our results were similar to that reported by Pollock et al and Zupanska et al. 
who reported that when IgG3 was present along with IgG1, hydrops developed earlier as 
compared to IgG1 alone and they reported that presence of IgG1 and IgG3 in combination 
resulted in greater rate of hemolysis in the fetus.(4)(103) There are studies with conflicting 
results and while some have found IgG1 and IgG3 together to be more significant, others 
have reported IgG1 alone as a major cause of severe HDFN.(3,74)(104) 
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The odds of developing severe disease also correlated with the antibody titre levels, and was 
found to be seven times higher when titre levels increased from <64 to 128-256 and finally  
greater than 512 (p=0.008, CI 1.69-33). This helped understand that each of these factors 
plays a role in prognosticating the severity of HDFN and either cannot be looked upon in 
isolation. The reports on HDFN severity and IgG subclass have been controversial, and 
against this background Shanfield et al.in 1980, reported that the severity of HDFN in 
mothers with IgG1 alone was dependent on the titre levels of the antibodies. However Iyer et 
al found no such correlation and observed that even mothers with low titre levels of IgG1 had 
babies with severe HDFN.(74) We did not find a significant difference in titre levels of 
antibodies between patients negative for IgG1/IgG3 and those having one or both of them. A 
similar result was observed between women with one of the IgG subclasses (IgG1 or IgG3) 
as compared to those with both. However Pearson Chi square and logistic regression analysis 
helper to infer that the titre level independently continued to impact the severity of HDFN, 
which was not associated with the subclass present. 
In present clinical practise high risk pregnancies with antibody screen positivity are followed 
up with antibody titre levels. We found the antibody titre levels to be significantly different 
between newborns with “no/mild” disease and those with “moderate/severe” disease. Since 
we observed the odds of disease to increase when IgG1 was present in a combination with 
IgG3, we analysed the difference in titre levels between patients with one of these subclasses 
(IgG1 or IgG3) to those with both these subclasses, there was no significant difference 
noticed in these two groups.  
We further compared the disease severity among low and intermediate titre groups of patients 
with neither, IgG1 or IgG3 and those with one or both of these. This was found to be 
extremely significant- helping us infer that even in low titres IgG1 and IgG3 might required 
closer follow up and are more likely to cause moderate to severe disease. 
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A binary logistic regression analysis was done to compare the odds of developing severe 
disease when IgG subclass, antibody titre levels and the IAT strength  were taken together, 
and this came to be 6.9 (p <0.05 and CI of 1.9 to 32). The odds of severe HDFN increased 
seven times through binary logistic regression when comparing No IgG1/IgG3 to IgG1/IgG3 
to further a combination of the two. 
In view of no clear cut guidelines in grading HDFN and since the treatment modality is 
guided by disease severity and subjective clinical decision, we also compared our DAT 
results to the HDFN in newborns. We found a strong correlation between the DAT result of 
the newborn and the severity of HDFN (p<0.001). DAT results itself have been controversial 
in their predictive ability of HDFN and there are different studies with contrary results. 
According to Song et al. they found that 96% of cases with a non-ABO incompatibility 
leading to HDFN the DAT was positive.(105) However Dinesh et al. who looked at the 
positive predictive value of DAT for HDFN found it to be only 23%, with the sensitivity of 
the test itself being, 86%.(66) But for our patient population of the 36 newborns with a DAT 
positive result, 27 required further treatment and close monitoring. 
Our results helped us identify, that almost 50% of our antenatal alloimmunized population 
have either IgG1 or IgG3 or a combination of these two subclasses. We also inferred that that 
the odds of developing HDFN progressively increased when either one or both these 
subclasses were present in the maternal serum. Since even in overall low titres IgG1and/or 
IgG3 was found to cause significant disease as compared to those who had neither, the 
relevance of this test was highlighted. We realized that CAT being a simple and easily 
available platform can be used in blood banks to offer clinicians another mean to monitor 
pregnancies at a higher risk of HDFN.  
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LIMITATIONS OF THE STUDY: 
 
The limitations of this study included, 
1. Most of our patients (85%) are from Tamil Nadu, and hence it may not be able to 
extrapolate our findings regarding IgG sub class as representative of the South Indian 
population, as we had hoped it to be. 
2. Secondly, 17 of our patients were lost to follow up. Since ours is a tertiary referral 
centre, many patients do not come for the final delivery if the antenatal period was 
uneventful or after an initial assessment here they carried on their antenatal check up 
at a place closer to home. 
3. Assessment of IgG subclass effect for antibodies other than anti D was not possible as 
they formed a very small part of the study group and could not be studied separately. 
4. The severity of disease was graded based on the treatment modality required. 
However varied studies have used different methods of grading and there is no 
evidence based guideline for the same. 
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CONCLUSION: 
 
 The IgG1/ IgG3 subclass prevalence in our antenatal alloimmunized population was 
overall 49%, with 20% being contributed by IgG1 only, 4% by IgG3 alone and  25% 
by a combination of IgG1 and IgG3. The remaining 51%were negative for both, IgG1 
or IgG3 subclass. 
  A strong association is seen between the severity of HDFN and IgG1/IgG3 subclass 
positivity (P< 0.001) when compared to women negative for IgG1 /IgG3) 
 The odds of developing severe HDFN increased progressively when comparing 
women who were negative for IgG1 / IgG3 to those with IgG1 or IgG3 and further 
increased when comparing those who had both IgG1 and IgG3(Odds ratio 6.9, p<0.05 
and CI between 1.9-32). 
  Comparing outcome in women with titres of <256, severity of HDFN was 
significantly greater in babies born to mothers with IgG1 / IgG3 subclass positivity 
(p< 0.001).  
 Strength of DAT (3-4+ compared to <2+) correlated significantly with severity of 
HDFN( P<0.001). 
 The test, performed using the CAT is a feasible test, which if implemented can 
contribute significantly to clinical decision making algorithms and appropriate timely 
interventions in the context of antenatal alloimmunization and HDFN. 
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Study of IgG subclass (IgG1/IgG3) in antenatal alloimmunized women and severity of 
HDFN 
Department of Transfusion Medicine and Immunohematology 
Christian Medical College, Vellore 
Name of patient  Unique study no.  
Age/DOB  Telephone no.  
Husband’s name  Address  
Hospital no.  
EDD  
 
 
Mother’s information 
 
Blood group  ICT   
Period of gestation  Antibody-identified  
Obstetric formula/ 
obstetric history 
 
IgG subytpe  
Outcome of pregnancy  
H/O transfusion  Husband’s group  
 
 
Newborn’s information 
Hospital no.  Hospital stay Day1 Day2 Day3 
Live/Still born/ IUD  Haemoglobin    
Pre/Term/Post  Bilirubin (D/I)    
Normal/LSCS  RBC count    
Sex  Retic count    
Weight at birth  Peripheral blood 
smear 
   
Thesis Data Form 
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(in gms) 
Blood group  Treatment required YES   /  NO 
DCT  
Cord blood Hb 
 
 
 
Treatment details 
IUT 
Phototherapy 
Exchange transf. 
None 
(Including no. of times and other details) 
Cord blood Bilirubin 
 
 
 
Jaundice 
Pleural effusion 
Ascites 
Hypoalbuminemia 
Acidosis 
Hydrops 
Kernicterus 
Coagulopathies 
Sepsis 
Y   /    N 
Y   /    N 
Y   /    N 
Y   /    N 
Y   /    N 
Y   /    N 
Y   /    N 
Y  /     N 
Y  /     N 
 
Remarks  
 
 
